Effects of Thyroid hormone on Cardiomyocytes and on Glioma differentiation and proliferation by Liappas, Alexandros
EFFECTS OF THYROID HORMONE ON 
CARDIOMYOCYTES AND ON GLIOMA 
DIFFERENTIATION AND PROLIFERETION 
 
Alexandros Liappas BSc, MSc 
 
 
A thesis submitted in partial fulfillment for the requirements for 
the degree of Doctor of Philosophy at the University of Central 
Lancashire in collaboration with the University of Athens 
Medical School, Greece. 
 
 
School of Pharmacy and Biomedical Sciences 
August 2012  
2 
 
Abstract 
The action of thyroid hormone (TH) on cell growth, differentiation and survival 
during development may be of therapeutic relevance. The present study investigated 
the potential effects of long-term TH treatment on cardiomyocytes and on glioma 
tumour cell lines. This study employed neonatal cardiomyocytes, 1321N1 cell line, an 
astrocytoma grade II, and U87MG, a glioblastoma grade IV. Cells were exposed for 2 
and 4 days in culture medium deprived of T3 (non-treated cells) and in a medium 
containing either 1 nM T3 (at near physiological range) or 500 nM T3 
(supraphysiological). From the initial study on cardiomyocytes, the results show that 
phenylephryne (PE) can induce cell growth and this effect was mediated by T3. For 
the glioma cell lines the results show that T3 at 1 nM can promote cell re-
differentiation in both cell lines. However, T3 had a preferential effect on suppressing 
cell proliferation only in the high grade glioma cell line. Thus, in 1321N1 cell line, T3 
increased cell proliferation (2 days) which declined thereafter (4 days) without having 
any effect on cell survival. In U87MG cell line, T3 resulted in marked suppression of 
cell proliferation without increasing cell injury. At the molecular level, a 2.9 fold 
increase in the  expression of TRα1 receptor was observed in U87MG cells as 
compared to 1321N1, p<0.05. TRβ1 receptor was undetectable in both cell lines. 
These changes corresponded to a distinct pattern of growth signalling activation 
induced by T3 treatment. The results also show that T3 had no significant effect on 
ERK activation in both cell lines, but significantly (p<0.05) increased phospho-Akt 
levels in 1321N1 cell line. At higher dose, T3 also induced cell differentiation in both 
cell lines and suppressed proliferation while increased cell injury in U87MG cells. It 
can be concluded from these results that T3 can re-differentiate glioma tumour cells. 
However, the effect of T3 on cell proliferation appears to be dependent on the type of   
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tumour cell line with aggressive tumours to be more sensitive to thyroid hormone 
treatment. TRα1 receptor may, at least in part, be implicated in this response. 
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1.1. General introduction 
Brain tumours are masses of growth of abnormal cells in the brain and typically are 
categorized as either primary or secondary. Primary brain tumours originate in the 
brain and can be non-cancerous (benign) or cancerous (malignant). Secondary brain 
tumours result from cancer that began elsewhere and has spread to the brain. Primary 
brain tumours are less common than secondary brain tumours (Aminoff, 2004). 
Benign brain tumours are usually slower growing, easier to remove (depending the 
location), and less likely to recur than are malignant brain tumours. Benign brain 
tumours do not invade the surrounding normal brain of other nearby structures, but 
they can still place pressure on sensitive areas of the brain. Malignant brain tumours 
can grow more rapidly, invading or destroying nearby brain tissue. However, unlike 
cancers elsewhere in the body, primary malignant brain tumours rarely spread from 
the brain (Aminoff, 2004). 
Signs and symptoms of the brain tumour depend on its size, location and rate of 
growth (Aminoff, 2004).  
A brain tumour- either primary or secondary- may cause a variety of signs and 
symptoms because it may directly press on or invade brain tissue. This can damage or 
destroy areas responsible for sight, movement, balance, speech, hearing, memory or 
behaviour. Pressure from a brain tumour can also cause surrounding brain tissue to 
swell (oedema), further increasing pressure and symptoms (Aminoff, 2004). 
Since it is not known exactly what causes primary brain tumours, it is difficult to 
pinpoint risk factors. In rare cases, brain tumours strike several members of a family, 
suggesting heredity may be a risk factor. This accounts for only a fraction of cases. 
Some types of brain tumours appear to occur more frequently in people who are   
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exposed in radiation or certain chemicals, such as those who work in oil refining, 
rubber manufacturing, and chemical and nuclear industries (American Cancer 
Society, 2007). However, a definite link between exposure to chemicals and brain 
tumours has not been proved. Similarly, electromagnetic fields and the use of cell 
phones have been studied as causes of primary brain tumours, but no definitive 
evidence indicates that either are the cause of brain tumours (American Cancer 
Society 2007; Munchi 2011; Cardis et al., 2011). 
This study is concerned mainly with gliomas, a type of brain tumour which derives 
from astroglial cells and which have attracted much recent attention. In particular, this 
thesis focuses on the pontential role of thyroid hormone (TH) signalling in gliomas. 
 
1.2. Gliomas 
Gliomas are the most common tumour of the central nervous system (CNS) with a 
lethality rate approaching 80% in the first year of diagnosis and comprise about 5% of 
all newly diagnosed cancers each year (Avgeropoulos et al., 1999; Lemke, 2004). 
Generally, the incidence of malignant gliomas equals that of leukaemia and comprises 
about 50% of all intracranial tumours in the adult. The American Cancer Society 
estimated that the number of new cases of primary CNS malignant disorders was 
16,500, per year with an estimated 13,000 deaths in the USA alone in 2000 (Greenlee 
et al., 2000). In the USA, about 7,000 cases of malignant brain tumours were newly 
diagnosed in 1987 (Kimmel et al., 1987) whilst in American’s Cancer Society survey 
in 2007 it was found that almost 20,500 new cases of malignant brain tumours were 
diagnosed. In the UK the average annual incidence of cerebral glioma in the age range 
15-64 years was 5.9 per 100,000 per year (Grant et al., 1996) and a later study showed   
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that glioblastomas have an incidence with 3.55 new cases per 100,000 population per 
year (Ohgaki and Kleihues, 2007). 
These neoplasms cause a disproportionate burden of cancer-related disability and 
death. The five year survival rates for brain tumours are the third lowest among all 
types of cancer (pancreas and lung are first and second, respectively) (Avgeropoulos 
et al., 1999). 
In the USA, the median survival of patients with gliomas treated conservatively is 14 
weeks; by surgical resection alone 20 weeks; by surgery and radiation 36 weeks; and 
by the addition of chemotherapy 40-50 weeks (Salcman, 1980; Fine et al., 1993; 
Salcman et al., 1994; Huncharek et al., 1998; Avgeropoulos et al., 1999; Stupp et al., 
2005; Tabatabai et al., 2012; Weller et al., 2012). 
Genetic mutations, specifically gene p53 chromosome 17, have been identified in 
50% of cancers and 75% of glioblastoma multiform (Madjian et al., 1999; Ali et al., 
2000; Gutin et al., 2000; Strickler et al., 2000; Caruthers, 2001; Paterson, 2001; 
Hickey, 2004; Ohgaki and Kleihues, 2007). Additional agents suspected as being 
carcinogenic include non-ionizing radiation (from cell phones and microwaves), 
pesticides, toxic water and high voltage power lines (American Cancer Society, 
2007). Current research investigating these agents remains inconclusive. 
Finally, the presenting symptoms of brain cancer are related to the decompensation of 
the brain resulting from an expanding mass. According to the ‘Monroe Kelly Theory’; 
equilibrium must be maintained between three components within the skull: brain 
tissue (80%), cerebral spinal fluid (10%) and interstitial and vascular supply (10%). If 
there is enlargement of one of these components or an expanding mass within the 
skull, there will be compression to one or both of the other components (Hickey,   
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2004). As the brain tumour grows, oedema will occur, which further compromises the 
closed system (Strickler et al., 2000; Caruthers, 2001; Hickey, 2004). Symptoms 
occur when the brain is no longer able to compensate for the increase in mass effect, 
and include headaches, seizures, or neurologic deficits (Chamberlain et al., 1998; 
Armstrong et al., 2000; Chang et al., 2000; Short et al., 2000; Strickler et al., 2000; 
Caruthers, 2001; DeAngelis, 2001; Peterson, 2001; Lovely, 2002; Hickey, 2004). 
High-grade tumours, such as anaplastic astrocytoma and glioblastoma multiforme 
(WHO grade III and IV, respectively), account for roughly half of astrocytic tumours 
(Cavenee et al., 2000) and are referred to as high-grade gliomas (Table 1.1). 
Depending on the cell origin, there are three main types of glial tumours: astrocytoma, 
oligodendroglioma andependymoma. The term ‘glioma’ generally refers to an 
astrocytoma. Furthermore, astrocytomas account for the majority of malignant 
gliomas in adults and are graded into four groups according to the WHO 
classification. Grade I tumours are more common in children than in adults and 
comprise a distinct entity called pilocytic astrocytomas, characterized histologically 
by the presence of Rosenthal fibres. Hypercellularity and cellular pheomorphism are 
the basic characteristics of grade II astrocytomas, whilst grade III astrocytomas show 
strong mitotic activity along with hypercellularity and pleomorphism (Ohgaki and 
Kleihues, 2007). 
When the tumour shows vascular endothelial proliferation and/or the presence of 
necrosis, it is graded as grade IV (Glioblastoma). Grade III and IV astrocytomas are 
generally referred to as malignant astrocytomas. Oligodendrogliomas and 
ependymomas are much less common and have three grades I, II, and III. Molecular  
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biology studies suggest two types of glioblastoma, primary (de novo) and secondary 
(evolving from a pre-existing low-grade glioma). 
Primary tumours exhibit frequent occurrences of loss of heterozygosity 10q (70% of 
cases) EGRF (Epithelial growth factor receptor) amplification (36%), p16
INK4a
 
deletion (31%) and PTEN mutations (25%), whereas secondary tumours show more 
frequent p53 mutation (Benjamin et al., 2003; Ohgaki and Kleihues, 2007). 
Surgery, radiotherapy or chemotherapy are the main treatment options and may be 
used alone or in combination, depending on the type of tumour. Surgery is the first 
treatment option for most primary brain tumours. As much of the tumour as possible 
is removed by making an opening in the skull called a craniotomy. A course of 
radiotherapy and/or chemotherapy often follows (Mao et al, 1991). 
Radiotherapy works by targeting radiation to damage the cancer cells and prevent 
them growing. It may be used before surgery to reduce the size of the tumour, after 
surgery to kill any tumour cells that were not removed, or as an alternative to surgery 
(Frelick et al, 1992) 
Chemotherapy uses drugs that attack cancer cells or prevent them multiplying. It is 
used alone or in combination with radiotherapy to treat primary brain tumours that 
cannot be removed surgically, or to treat secondary brain tumours. It is usually given 
as tablets or by injection (Davis et al, 1991). 
Steroids, such as dexamethasone, are often given to reduce the swelling caused by 
brain tumours. They will not remove the tumour, but should improve the symptoms 
and may be given before or after surgery of radiotherapy (Riggs et al, 1995). 
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1.3. Identification and grading of brain tumours 
Gliomas (cancer cells) are identified depending on the specific cell type they largely 
bear a resemblance to or originate from (Table 1.1). There are three main types of 
glioma; astrocytomas originating from astrocytes, oligodendroglioma 
(oligodendrocytes) and ependymomas (ependymal cells), (World Health Organization 
WHO 1990). Gliomas are further categorised into a grading system by histological 
examination. Many different methods are employed to grade tumours but the one 
most commonly used is that of the World Health Organisation (WHO). The WHO 
grading system grades gliomas into 4 categories, grades I-IV, I being the least 
aggressive and IV being the most aggressive, prognosis is strongly related to 
histological grade (Table 1.1).   
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Table 1.1. Summary of grading system for astrocytomas. Table obtained from WHO 
(World Health Organisation 2007). 
Grading of astrocytomas 
WHO Grade Designation Histological Criteria 
I Pilocytic Astrocytoma Rosenthal fibres, eosinophilic 
granular bodies and 
microcystes 
II Diffuse Astrocytoma Nuclear atypia, 
hypercellularity and 
pleomorphism. 
III Anaplastic astrocytoma Nuclear atypia and strong 
mitotic activity 
IV Glioblastoma 
multiform 
Atypia, mitoses, vascular 
endothelial proliferation, 
necrosis 
 
Grade I glioma or pilocytic astrocytomas are considered to commonly be a childhood 
tumour as they occur predominantly in children, involving the midline, posterior and 
basal fossae. They are characterised histological by the presence of Rosenthal fibres, 
eosinophilic granular bodies and microcystes (Nishio et al, 1995). Grade II gliomas 
are termed diffuse astrocytoma and often show evidence of hypercellularity and 
cellular pleomorphism (Surawicz et al, 1999). Grade III glioma or anaplastic 
astrocytoma occur mainly in adults with a median age at diagnosis of 51 years of age 
and account for roughly 7% of primary brain tumours. They exhibit strong mitotic 
activity along with hypercellularity and pleomorphism (Bondy et al, 1991). Grade IV 
glioma or glioblastoma multiform (GBM), is the most common form of glioma   
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accounting for roughly 45%-52% of all reported brain tumours. These are the most 
aggressive tumours and often recur which contributes to the poor survival time 
associated with these tumours. GBM are distinguished from grade III glioma by the 
presence of necrotic tissue alongside proliferating anaplastic cells, grade III glioma 
has no necrotic tissue. Within both the different areas of the same tumour and 
between different GBM’s there is often discernible heterogeneity in histological and 
cytological appearance (Preston-Martin et al, 1995; Christians et al., 2012; Karina et 
al., 2012; Gupta et al., 2012). 
Over the past few decades there has been increased interest in glioma research with 
new and more effective ways of treating glioma; nonetheless improvement in 
prognosis has been limited  (Li et al., 2012; Minniti et al., 2009). Because of their 
profound devastating effect much research is currently being carried out to investigate 
gliomas and it seems that the chemosensitivity of gliomas, i.e. the analysis of glioma 
response to a specific drug, is a focal point of developing treatment, and more recently 
an idea of prevention (Gurney et al, 1996). 
 
1.3.1. Astrocytic tumours 
Astrocytomas are defined as tumours composed predominantly of neoplastic 
astrocytes. If not stated otherwise, this term applies to diffusely infiltrating neoplasms 
which, according to their biological behavior, are subdivided into low grade 
astrocytoma (WHO Grade II), anaplastic astrocytoma (WHO Grade III) and 
glioblastoma (WHO Grade IV) (Dillman et al, 2004). A distinct entity is the pilocytic 
astrocytoma, which has a different location, age distribution, biological behavior and 
genetic basis (Chan et al, 2005).  
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The term astrocytoma was already used in the late nineteenth century by Virchow 
(Barker et al, 1998) but was firmly introduced into histopathological classification in 
1926 by Bailey (Cushing Brem et al, 1995). A detailed account of the historical 
evolution of the astrocytoma terminology has been given by Zulch (Amiratti et al, 
1987) and Russell and Rubinstein (Choucair et al, 1986). More recent reviews on the 
pathology of astrocytic neoplasms include those by VandenBerg Cohen et al, (1995), 
Davis et al, (1998), Schiffer Kleihues et al, 2000, Parisi and Scheithauer, (Mahajan et 
al, 2005), and Burger and Scheithauer, (O'Reilly et al, 2006). 
 
1.3.2. Pilocytic astrocytomas 
The pilocytic astrocytoma is a slow growing astrocytic tumour predominantly of 
childhood, with preferential location in midline structures of the CNS.  The term 
piloid/ pilocytic astrocytoma was introduced by Penfied in 1931 (Salcman et al, 
1994). Pilocytic astrocytoma is now the generally acknowledged term and 
recommended in the WHO Histopathological Typing of Tumours of the CNS (Stupp 
et al, 2002; Black et al, 1991). Pilocytic astrocytoma amounts to approximately 6% of 
intracranial tumours. More than 75% of pilocytic astrocytomas manifest in children 
below the age of 20 years, and peak incidence is between 8 and 13 years (Aronen et 
al, 2002) 
Pilocytic astrocytomas are preferentially located axially, i.e. close to the ventricles 
and to midline structures of the CNS, i.e. visual system, hypothalamus, cerebellum, 
brain stem and spinal cord. The cerebellum is most frequently affected, preferentially 
the cerebellar hemispheres (>80%), less frequently the vermis (20%) (Colombo et al, 
2005).  
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Since pilocytic astrocytomas are slowly growing neoplasms, the clinical history often 
precedes clinical diagnosis and surgical intervention by several months, often years. 
In the cerebellum, the pilocytic astrocytoma is macroscopically well delineated and 
appears to expand rather than infiltrate into adjacent brain structures. Pilocytic 
astrocytomas may display a remarkable degree of nuclear polymorphism; even 
multinuclear giant cells may occur.  Vascular proliferation may be extensive and often 
includes formation of typical glomeruli (Yoshida et al, 2000; Scharfen et al, 1992). 
Cytogenetic analysis of pilocytic astrocytomas was revealed either or a normal 
karyotype of a variety of aberrations but no distinct pattern suggesting the loss of a 
particular tumour suppressor gene (Osoba et al, 2000; Mahajan et al, 2005) with the 
exception of a frequent (33%) occurrence of trisomy 7 and 8 (O'Reilly et al, 2006). In 
contrast to diffusely infiltrating astrocytomas, pilocytic astrocytomas have no intrinsic 
tendency for progression to malignant astrocytoma. 
 
1.3.3. Diffuse astrocytomas  
Astrocytic neoplasms are characterized by a high degree of cellular differentiation, 
slow growth and diffuse infiltration of neighbouring brain structures. These lesions 
typically affect young adults and have an intrinsic tendency for malignant progression 
to anaplastic astrocytoma and ultimately, glioblastoma. The term ‘diffuse 
astrocytoma’ refers to low grade astrocytomas of adults (Kleihues et al., 1993). 
Diffuse astrocytomas represent 10-15% of all astrocytic tumours, with an incidence of 
approximately 1.4 new case per 1 million population per year (Davis et al., 1998) the 
  
27 
 
peak incidence occurs in young adults between 30 and 40 years of age (25% of all 
cases). Diffuse astrocytomas may be located in any region of the CNS. 
Seizures are a common presenting manifestation of tumour. It is clear that the 
symptoms and the signs of the patient depend upon the location of the tumour. 
Diffuse astocytomas are composed of well-differentiated fibrillary or gemistocytic 
neoplastic astrocytes. Cellularity is moderately increased and occasional nuclear 
atypia is a typical feature. Mitotic activity is generally absent and the presence of 
necrosis or microvascular proliferation is incompatible with the diagnosis of diffuse 
astrocytoma (Kleihues and Cavenee, 1999) 
 
1.3.4. Low grade diffuse astrocytomas 
Low grade diffuse astrocytomas progressing to glioblastomas present mutation 
frequencies on TP53 of greater than 60% (Reifenberg et al., 1996; Watanabe et al., 
1997). Frequency of TP53mutation does not increase during malignant progression of 
low grade atsrocytomas indicating that this genetic change is an early event (von 
Deimling et al., 1992; Sidransky et al., 1992; Watanabe et al., 1996; Watanabe et al., 
1997; Ruda et al., 2012; Hasegawa et al., 2011). If the mutations were the initial event 
(Kinzler et al., 1998) it would be expected that patients with inherited TP53 germline 
mutations would also develop brain tumours preferentially of astrocytic lineage and 
this is indeed the case (Kleihues et al., 1997). Other genetic changes observed in 
diffuse astrocytomas concern platelet derived growth factor receptor α (PDGFRα). 
Mean survival after surgical intervention shows a range of 6-8 years (Roelcke et al., 
1999). The total length of disease is mainly influenced by the dynamics of malignant  
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progression to glioblastoma, which tends to occur after a mean time of 4-5 years 
(Vestosick et al., 1991; McCormack et al., 1992; Watanabe et al., 1997; Roelcke et 
al., 1999). 
 
1.3.5. Fibrillary astrocytomas 
This is by far the most frequent histological variant of astrocytoma. The occasional or 
regional occurrence of gemistocytic neoplastic cells is compatible with the diagnosis 
of fibrillary astrocytomas (Maxwell, 1991). 
 
1.3.6. Gemistocytic astrocytomas 
This variant of astrocytoma is predominantly composed of gemistocytic neoplastic 
astrocytes. The gemistocytic neoplastic astrocytes consistently express GFAP (like 
most of the gliomas do) in their perikarya and cell process. Electron microscopy 
confirms the presence of abundant, compact glial filaments in the cytoplasm and in 
the cell progress. Enlarged mitochondria have also been noted (Choucair et al, 1986; 
Combs et al, 2005). 
 
1.3.7. Protoplasmic astrocytomas 
This rare variant is characterized by neoplastic astrocytes showing a small cell body 
with few, thin processes with a low content of glial filaments. Nuclei are uniformly 
round to oval. Cellularity is low and mitotic activity absent (Jaeckle et al, 2003).  
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1.3.8. Anaplastic astrocytomas 
The anplastic astrocytoma is a diffusely infiltrating tumour with focal or dispersed 
anaplasia and a marked proliferative potential. These tumours rise from low-grade 
astrocytomas but also diagnosed at biopsy without a less malignant precursor lesion 
and have an intrinsic tendency for malignant progression to glioblastoma. The 
anplastic astrocytoma corresponds to WHO grade III. The main incidence of these 
tumours occurs between 40 and 49 years of age in males and 30-39 years for females 
(Kleihues and Cavenee 1999). Moreover, they are more frequent in males than 
females with a male to female ratio of 1.8:1. Localization corresponds to that of other 
diffusely infiltrating astrocytomas, with a preference for the celebral hemispheres. 
Symptoms are similar to those referred to previously for patients with diffuse 
astrocytomas WHO grade II (Kleihues and Cavenee 1999). 
The principal histopathological features of anplastic astrocytoma are those of diffuse 
infiltrating astrocytomas with increased cellularity, distinct nuclear atypia and marked 
mitotic activity (Watanabe et al., 1997). 
Anaplastic astrocytoma show a high frequency of TP53 mutation similar to that of 
diffuse astrocytomas found in over 90% of the cases (Watanabe et al., 1997) 
additional genetic changes reflect the high degree of malignancy such as RB 
alterations (25%), p19
ARF 
deletion (15%) and CDK4 amplification (10%) (Kleihues 
and Cavenee 1999). Also PTEN/MMAC1 mutations and LOH on chromosome 10q 
have been reported in 15% and 30% respectively (Kleihues and Cavenee 1999). 
Finally, approximately 40% of anaplastic astrocytoma have shown a LOH on 
chromosome 19q (von Deimling et al., 1994) and in 30% a LOH on chromosome 22q 
(Ischimura et al., 1998).  
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The key prognostic factor is progression of anplastic astrocytoma to glioblastoma. 
The time interval varies with a mean of 2 years (Watanabe et al., 1997) and a total 
length of disease of 3 years (Donahue et al., 1997). 
 
1.3.9. Glioblastomas 
Glioblastoma multiform (GBM) is the most aggressive form of primary brain tumours 
known collectively as gliomas. These tumours arise from the supporting, glial cells of 
the brain during childhood and in adults. These growths do not spread throughout the 
body like other forms of cancer, but cause symptoms by invading the brain (Scott et 
al, 1998). Gliomas are graded by their microscopic appearance. As a rule, their 
behaviour can be predicted from this histology: grade I (pilocytic astrocytomas) and 
grade II (benign astrocytomas) tumours grow slowly over many years while grade IV 
(GBM) grows rapidly, invading and altering brain function. Untreated, GMB’s are 
rapidly lethal (Sipos et al, 1997). 
The area of the brain first involved by the tumour influences the first symptoms of 
GMB. Progressive weakness, speech or visual loss occurs when "eloquent" brain 
regions are involved. More "silent" areas of the brain allow the tumours to become 
large before symptoms arise. In this case increased pressure in the head produces 
headache and rarely, visual loss from swelling of the optic nerves (Tuettenberg et al, 
2005). The tumours also irritate the brain, causing epileptic seizures. Rarely, 
spontaneous haemorrhage into the tumour yields a stroke syndrome, with the sudden 
development of a neurological deficit. 
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GBM usually raise de novo or may develop from lower grade gliomas after many 
years. Distinct genetic alterations in primary and secondary GBM’s have been 
identified. As a rule, they do not run in families (Wald et al, 1997). Once symptoms 
occur, the diagnosis of GBM is usually straightforward. The tumour can be imaged by 
contrast-enhanced MRI scan. Progressive growth of the lesion on serial MR scans 
differentiates tumour from stroke. A PET scan showing increased uptake of glucose 
can also help separate a diagnosis of tumour from stroke. An open or needle biopsy 
provides tissue for microscopic diagnosis. Glioblastoma is the most frequent brain 
tumour and accounts for approximately 12-15% of all intracranial neoplasms 
(Lurching et al, 1975), and 50-60% of all astrocytic tumours. The incidence in the 
general population is in the range of two to three new cases per 100000 per year for 
most European and North American countries. Glioblastomas may manifest at any 
age, but preferentially affect adults, with a peak incidence between 45 and 70 years 
(Brandes et al, 2002). 
The preferred location of glioblastomas is the cerebral hemispheres, in particular the 
frontotemporal and parietal regions. Tumour infiltration often extends into the basal 
ganglia. Glioblastomas of the brain stem (malignant brain stem glioma) are less 
frequent and often affect children (Dillman et al, 2004), while cerebellum and spinal 
cord are rare sites for this neoplasm.  It has long been observed that some 
glioblastomas develop over months or years from low grade or anaplastic 
astrocytomas and these have traditionally been termed secondary glioblastomas. The 
less malignant precursor lesions usually manifest at middle age (30-45 years). In 
contrast, primary glioblastomas develop with a short clinical history of usually less 
than 6 months de novo, i.e. without clinical or histopathological evidence of a pre-
existing, less malignant precursor lesion (Groves et al, 2002).  
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1.4. Molecular aspects of glioma tumourigenesis 
1.4.1. Growth kinase signalling in cell proliferation and survival  
1.4.1.1. MAPK and cancer 
Mitogen-activated protein kinases (MAPKs) are serine-threonine kinases that mediate 
intracellular signalling associated with a variety of cellular activities including cell 
proliferation, differentiation, survival, death and transformation (McCubret et al., 
2006, Torii et al., 2006; Dhillon et al., 2007). MAPK pathways are usually activated 
through complex signalling that contains multiple kinases guided by scaffold protein 
or as a result of binary interactions between kinase components. Kinase suppressor of 
Ras-1 (KSR) and MEK partner 1 (MP1) function as scafford proteins for the ERK 
signaling pathway (Morrison et al., 2003; Whitmarsh et al., 2006). 
In the ERK signalling pathway, ERK1 or ERK2 is activated by MEK1/2, which in 
turn is activated by a Raf isoform such as A-Raf, B-Raf or Raf-1. Members of the Ras 
family of protein play a key role in transmission of extracellular signals into the cell 
(Malumbres et al., 2003). 
Associated with cellular activities the MAPK signalling pathways have been 
implicated in the pathogenesis of many human diseases such as cancer, Alzheimer’s, 
Parkinsons and amyotrophic lateral sclerosis (Dhillon et al., 2007). 
Ras and B-Raf that play a key role in the ERK signalling pathway have been 
associated in many cancer mutations (Dhillon et al., 2007; Boutros et al., 2008). 
Activated MEK1/2 has also been shown to up-regulate the expression of matrix 
metalloproteinases and to protect cancer cells from anoikis or detachment- induced 
apoptosis (Voisin et al., 2008).  
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ERK signalling plays a role in several steps of tumour development, and also induces 
the expression of matrix metalloproteinases promoting the degradation of 
extracellular matrix proteins and consequent tumour invasion (Chakraborti et al., 
2003). 
Furthermore, ERK1/2 signalling regulates both the activity and levels of Bcl-2 family 
proteins such as the pro-apoptotic protein BIM and the anti-apoptotic protein MCL-1, 
thereby promoting the survival of cancer cells (Balmanno et al., 2009). Mutations in 
the epidermal growth factor receptor (EGFR), which activates the ERK pathway, 
occur frequently in lung and colorectal cancers (Hynes et al., 2009, Nagahara et al., 
2005). The most common mutation of EGFR is an in-frame deletion in the tyrosine 
kinase domain, which results in activation of downstream signaling such as that 
mediated by the PI3K-Akt and Raf-MEK-ERK pathways (Fig 1.1) (Paez et al., 2004). 
Gefitinib and erlotinib, both inhibitors of the tyrosine kinase activity of EGFR, are 
used to block the proliferation of non-small cell lung cancer cells (Zhu et al., 2008). 
 
1.4.1.2. ERK 
Cell motility is a fundamental process that is required during normal embryonic 
development, wound repair, inflammatory response and tumour metastasis 
(Lauffenburger et al., 1996). The ERK pathway plays an essential role in the 
induction of epithelial cell motility in response to hepatocyte growth factor (HGF) 
(Tanimura et al., 1998). HGF-induced activation of the ERK pathway is linked to the 
expression of the matrix metalloproteinase (mmp)-9 gene, and MMP-9 activity is 
required for the induction of cell motility via the degradation of the extracellular 
matrix (Tanimura et al., 2002). Elevated expression of MMPs is associated with  
34 
 
increased metastatic potential in many tumour cells, and inhibition of MMP activity 
results in the reduction of tumour invasion and metastasis (Reddy et al., 2003). 
Transfection of a constitutive active form of MEK1 induces increased expression of 
MMP2/9 and confers metastatic potential to NIH3T3 cells (Welch et al., 2000). 
Implication of the ERK pathway in the activation of the motility machinery of the cell 
has been reported, in which ERK1/2 phosphorylates and enhances the myosine ligh-
chain kinase (MLCK) activity leading to increased MLC phosphorylation and 
enhanced cell migration (Klemke et al., 1997). 
Specific inhibition of the ERK pathway is expected to result in anti-metastatic as well 
as anti-angiogenic effects in tumour cell. Specific blockade of the ERK pathway has 
been shown to inhibit the disruption of cell-cell contact and motility required for the 
metastatic process in colon tumour cells (Sebolt-Leopold et al., 1999) and to inhibit 
the invasiveness of tumour cells through the down-regulation of MMP-3/-9/-14 and 
CD44 (Tanimura et al., 2003)  
 
1.4.1.3. Akt 
Akt delivers antiapoptotic signals via different proteins directly modulated by Akt 
phosphorylation. Bad (Bcl2 antagonist of cell death) is one of the first discovered 
targets of Akt phosphorylation. Bad is a proapoptotic member of the Bcl-2 family of 
proteins, able to bind Bcl-2 or Bcl- XL, blocking their antiapoptotic activities. 
Phosphorylation of Bad on S136 by Akt disrupts its interaction with Bcl- 2/Bcl-XL, 
localized on the outer mitochondrial membrane, sequestering Bad in the cytosol, 
through the interaction with 14-3-3 protein (Hirakawa et al., 1988). In an analogous 
way, phosphorylation by Akt of proapoptotic Bax protein on S184 suppresses its  
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translocation to mitochondria, preventing Bax conformational change, a typical event 
that occurs after apoptotic induction. In addition, the caspase cascade is further 
inhibited by Akt phosphorylation of procaspase 9, inactivatedthrough phosphorylation 
in S196, a residue that, however, is not conserved in other mammalian species (Crews 
et al., 1993). 
One of the best-conserved functions of Akt is its role in promoting cell growth. The 
predominant mechanism appears to be through activation of the mammalian target of 
rapamycin complex 1 (mTORC1), which is regulated by both nutrients and growth 
factor signalling.  Akt-mediated cell proliferation and oncogenic transformation has 
been shown to be dependent on mTORC1 activation (Bononi et al., 2011). 
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Figure 1.1: MAPK kinase signaling of tumour growth. (Figure modified from Hussam 
et al., 2010).  
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1.4.2. Growth kinase signalling in gliomas  
1.4.2.1. ERK and gliomas. 
Malignant glioma tumours can be induced and maintained by aberrant signalling 
networks such as the Ras pathway. Although somatic oncogenic mutations of Ras 
genes are frequent in several cancer types, early investigations on gliomas reveal 
disappointing facts that the Ras mutations are nearly absent in malignant gliomas and 
that the BRAF mutations are present in a very small percentage in gliomas. Therefore, 
the observed deregulation of the Ras-RAF-ERK signalling pathway in gliomas is 
attributed to its upstream positive regulators, including, EGFR and PDGFR known to 
be highly active in the majority of malignant gliomas (Lo, 2010). 
 
1.4.2.2. Akt and gliomas. 
Signalling through phosphatatidylinositol 3-kinase (Ptdlns3K)-Akt-mTOR is 
frequently activated in glioblastoma multiform (GBM), where this kinase network 
regulates survival. Inhibitors of these pathways induce minimal cell death in glioma. 
It has been shown that the dual Ptdlns3K-mTOR inhibitor PI-103 induces autophagy 
in therapy-resistant, PTEN-mutant glioma, with blockade of mTOR complex 1 
(mTORC1) and complex 2 (mTORC2) contributing independently to autophagy. 
Inhibition of autophagosome maturation synergizes with PI-103 to induce apoptosis 
through the Bax-dependent intrinsic mitochondrial pathway, indicating that PI-103 
induces autophagy as a survival pathway in this setting (Fan, 2011). 
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1.5. Current treatment for brain malignant tumours 
1.5.1. Surgery 
Surgery can include gross total excision of the tumour using image guidance, awake 
craniotomy, and cortical mapping or may be restricted to biopsy alone, depending on 
the site of the lesion and the condition of the patient. The goal of surgery is to 
completely resect the tumour. However the infiltrating nature of gliomas and their ill-
defined margins make this goal difficult. Therefore, most surgery attempts to reduce 
tumour bulk, alleviate raised intracranial pressure, obtain a diagnosis and removes 
hypoxic tissue resistant to chemotherapy. A study (Chang et al, 1983) from the RTOG 
(Radiation therapy and Oncology group) and eastern Cooperative oncology group 
showed an 18 month survival of 15% for biopsy alone, 25% for partial resection and 
34% for total resection. A retrospective review (Simpson et al, 1993) of 3 RTOG 
trials showed an 11.3 months median survival for gross total excision compared to 6.6 
months for biopsy alone. Whatever the nature of surgery, correct surgical planning is 
vital in minimizing morbidity from the procedure. Besides achieving maximum 
tumour resection it is also aimed at minimizing the risk of neurological deficits 
(Krishnam et al, 2004). 
Many recent advances in surgical techniques have helped to achieve this aim but have 
not demonstrated any significant difference in survival (Whittle, 2002). These 
advances include pre-operative functional imaging, fusion of functional and 
anatomical imaging for per operative neuronavigation, intra operative functional 
mapping and use of intra operative MRI. Intra-operatively obtained functional 
information remains of crucial importance especially when operating on tumours that 
are located in or adjacent to functional cortical sites and subcortical pathways (Keles   
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et al, 2004). The corticospinal motor evoked potential (D-wave) has been used for per 
operative evaluation of the corticospinal tract in patients under general anaesthesia. A 
decrease of D wave amplitude of less than 30% may indicate postoperative 
preservation of motor function, including transient motor disturbance with subsequent 
complete recovery. This technique may allow maximal resection of brain tumours 
located around the motor cortex (Yamamoto et al, 2004). Magnetic source imaging 
(MSI) is useful in the surgical decision making for lesions adjacent to functionally 
important brain areas (Ganslandt et al, 2004) whilst use of intra-operative MRI has 
shown to be useful in maximizing the tumour resection (Nimsky et al, 2004). 
Furthermore, the integration of functional magnetic resonance imaging (fMRI) data 
into neuronavigation are a useful concept to assess the risk of a new motor defect after 
surgery. A lesion to activation distance of less than 5 mm is associated with a higher 
risk of neurological deterioration whereas a complete resection can be achieved safely 
with a lesion to activation distance of more than 10 mm (Krishnam et al, 2004). 
Diffusion tensor (DT) magnetic resonance imaging to track fibres is being used to 
help image guided tumour resection with decreased morbidity (Berman et al, 2004). 
 
1.5.2. Radiotherapy 
Standard radiation treatment of glioma includes whole brain irradiation of 60 Gy with 
conventional external beam radiotherapy following surgery, in fractionated doses. The 
results of post-operative radiation therapy of malignant gliomas are disappointing, 
with mean survival time (MST) of 16-70 weeks and 2-year survival rates ranging 
from 8.5% to 25% in the literature. Only 10% of patients with glioblastoma and 44% 
of those with grade III gliomas will survive for more than 2 years following their   
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diagnosis (Burger et al, 1985). Interstitial brachytherapy and charged particle 
irradiation are being used mainly in lower grade glioma. The possibility of combining 
CT and MR Neuroimaging data together with stereotactic radiotherapy techniques 
enables the optimal development of the tree-dimensional treatment plane (Rubino et 
al, 2004). Due to infiltrative nature of glioma, conventional radiotherapy is not able to 
deliver curative doses without damaging the normal brain tissue. Radio-
immunotherapy is emerging as a novel technique because of the potential for more 
selectively irradiating tumour cells while sparing normal tissues. Therapeutic potential 
of monoclonal antibodies (MAB) labelled with the beta-emitters 
131
I and 
90
Y and the 
alpha-emitter 
211
Y is being investigated in brain tumours (Zalutsky, 2005) 
 
1.5.3. Chemotherapy 
Surgery followed by standard radiotherapy with concomitant and adjuvant 
chemotherapy with temozolomide is the standard of care in patients with 
glioblastoma, however the prognosis remains poor with a median survival in the range 
of 12-15 months (Stupp et al., 2005). Common genetic abnormalities in glioblastoma 
are associated with aberrant activation or suppression of cellular signal transduction 
pathways and resistance to radiation and chemotherapy. Special attention has been 
focused on targets such as epidermal growth factor receptor, vascular endothelial 
growth factor receptor, platelet-derived growth factor receptor, and on pathways such 
as the phosphatidylinositol-3kinase/Akt/mammalian target of rapamycin and 
Ras/Raf/mitogen-activated protein-kinase pathways. 
Despite extensive efforts at defining biological markers as a basis for selecting 
therapies, most treatment decisions for glioblastoma patients are still based on age and  
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performance status (Weller and Stupp 2012). Currently, surgery followed by standard 
RT with concomitant and adjuvant chemotherapy with temozolomide is the standard 
of care in patients with GBM aged <70 years. However, the prognosis remains poor, 
with a median survival of 12-15 months (Stupp et al., 2005). Clinical experience has 
revealed that gliomas sharing similar histomorphological criteria might indeed have 
different clinical courses and exhibit highly heterogenous responses to treatments 
(Tabatabai and Stupp, 2012). Overexpression, activation, and dysregulation of various 
membrane receptors, signalling pathways, and other factors may occur frequently in 
GBM (Kapoor et al., 2003; Kitange et al., 2003; Louis, 2006). 
Mammalian target of rapamycin (mTOR) have been examined in preclinical and 
clinical trials for malignant glioma. The efficacy of these agents as monotherapies has 
been modest, at best; however, new multitargeted kinase inhibitors and combinations 
of single-targeted kinase inhibitors in combination with radiation and cytotoxic 
chemotherapy will likely play an increasing role in the management of GBM and 
several randomized. 
 
1.5.3.1. Current Standard Therapy for GBM 
Temozolomide given concomitantly and adjuvantly with RT after surgical resection 
represents the standard of care in patients with GBM. The epigenetic silencing of 
MGMT by promoter methylation is correlated with improved survival in patients 
treated with temozolomide. Although the prolonged exposure of cancer cells to 
temozolomide may represent a promising strategy to overcome resistance mediated by 
MGMT, at present, the clinical relevance of the use of a dose-dense temozolomide 
schedule remains to be proven (Groot et al., 2007).  
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1.5.3.2. Targeted Therapies 
GBM is characterized by several aberrantly activated signalling pathways. Several 
growth factor receptors, such as epidermal growth factor receptor (EGFR), vascular 
endothelial growth factor receptor (VEGFR) and platelet-derivated growth factor 
receptor (PDGFR), are overexpressed, amplified and/or mutated, leading to 
uncontrolled cell proliferation, angiogenesis, migration, survival and differentiation 
(Sanson et al., 2004; Groot et al., 2007) (Figure 1.2). The major challenge in the use 
of targeted therapies is the identification of the optimal therapeutic targets, and to 
select new agents which can translate to survival benefit for patients with GBM. 
Currently, the use of small molecule tyrosine kinases inhibitors (TKIs) and 
monoclonal antibodies against EGFR and VEGFR have been evaluated in phase II 
clinical trials as main anti-growth factor receptor strategies. Other potentially useful 
agents for the treatment of GBM are represented by the PDGFR-, mammalian target 
of rapamycin (mTOR) and integrin inhibitors. 
 
1.5.3.3. EGFR Inhibitors 
Phosphorylation of the tyrosine kinase domain activates several signalling pathways, 
such as the phosphatidyl-inositol 3′-kinase (PI3K)/Akt/mTOR, and Ras/mitogen-
activated protein kinase (MAPK) (Normanno et al., 2006; Burgees et al., 2008). 
Activation of EGFR pathways results in several biological processes, including cell 
proliferation, angiogenesis, migration, survival and differentiation.  
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1.5.3.4. Mammalian Target of Rapamycin Inhibitors 
Overactivation of the PI3K/Akt/mTOR pathway seems to play an important role in 
gliomagenesis (Guertin et al., 2007). Combined activation of Ras and Akt leads to the 
formation of GBM in mice (Hu et al., 2007). In human GBM, Akt is activated in 
approximately 70% of these tumours, in association with loss of PTEN and/or 
activation of EGFR and PDGFR tyrosine kinases. Alterations of PTEN expression are 
present in 20-40% of GBM (Wang et al., 1997; Zhou et al., 1999), and have been 
associated with a worse prognosis, although conflicting results have been reported 
(Zhou et al., 1999; Sano et al., 1999; Ermoian et al., 2002). There is emerging 
evidence suggesting that mTOR is a critical downstream component in PTEN/Akt 
signaling (Schmelzle et al., 2000; Castedo et al., 2002; Podsypanina et al., 2001; 
Choe et al., 2003), and pharmacological inactivation of mTOR reduces neoplastic 
proliferation and tumour size in PTEN-deficient mice (Rajasekhar et al., 2003). These 
evidense has provided the rationale for clinical studies of mTOR inhibitors in GBM. 
Although data strongly support the view of the PTEN/PI3K/AKT pathway as an 
important target for drugs, current clinical results on the use of mTOR inhibitors 
remain disappointing. A new generation of trials is seeking to define whether the 
combination of two or more targeted drugs together with RT and cytotoxic 
chemotherapy can overcome tumour resistance. 
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Figure 1.2: Schematic representationof main oncogenetic signaling pathways and site 
of action of molecular targeted therapies. (Taken from Minniti et al., 2009).  
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1.6. Therapeutic approaches related to re-differentiation of cancer 
cells 
 
1.6.1. Cancer as maladaptive response to stress: a shift to a paradigm  
 
One of the main characteristics of pathological tissue is the re- expression of fetal 
characteristics. The physiologic significance of this rewind to foetal life remains 
largely unknown. However, this appears to be an evolutionary conserved mechanism 
related to stress response. Thus, return to foetal phenotype and cell dedifferentiation 
may be a prerequisite permissive state for regeneration after stress. De-differentiated 
cells have the ability to proliferate and/or grow and then to re-differentiate to 
specialized cells that comprise the regenerated structure or organ (Gurtner et al., 
2008). This mechanism appeared early in evolution and allowed living organisms to 
adapt to environmental stresses. In fact, salamanders have the ability to replace whole 
body parts or anurans can recover body parts at the embryonic stages through 
induction of cell dedifferentiation/re-differentiation processes (Pellettieri et al., 2007). 
Mammals retain the ability to regenerate but in a more restrictive form. For instance, 
neonatal mouse heart displays a regenerative potential early after birth in which 
differentiation is not complete (Schafer et al., 2008). This regenerative potential may 
be regained in adult life after stress-induced dedifferentiation and return to fetal 
phenotype. However, the ability of the cells to re-differentiate may be diminished 
upon intense and sustained stressful stimuli. This re-differentiation “deficit” may 
result in heart failure, cancer, and so forth (Tsonis et al., 2000), while interventions 
which potentially could enhance endogenous re-differentiation may restore tissue 
integrity and function (Figure 1.3).  
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Figure 1.3: Links between regeneration and cancer. (A) Regenerative events and their 
corollaries in cancer. Importantly, the process of regeneration can be repeated without 
causing malignant transformation, while in cancer the regenerative process is 
incomplete such that chronic injury and inflammation leads to continuous 
proliferation. This suggests that characterizing signals at later stages of regeneration 
(especially those involved in termination) may help identify candidates able to stop 
abnormal proliferative responses to chronic injury. (B) Regeneration can correct 
malignant transformation, as in newt limbs where amputation through the site of 
induced tumours results in the regeneration of a normal limb without tumours. (Taken 
from Nestor et al., 2009).  
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1.6.2. Thyroid hormone as novel cancer treatment  
 
Studies on the amphibian metamorphosis,  which is  one of the natures’ paradigms of 
tissue and organ remodelling have revealed an evolutionary conserved mechanism of 
organ formation  and repair entirely dependent on thyroid hormone (Sato et al., 2007). 
Gudernatsch,  almost 100 years ago,  made the remarkable discovery that equine 
thyroid extracts could accelerate the metamorphosis of tadpole into juvenile frogs 
(Figure 1.4) (Gudernatsch, 1912). Since then, several studies, if not all, have shown 
that the morphological and functional changes of metamorphosis are the result of 
alterations in the transcription of specific sets of genes induced by TH (Berry et al., 
1998; Furlow et al., 2004; Furlow and Neff, 2006; Shi et al., 2001). 
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                             Pre-metamorphosis period    metamorphosis period  
Figure 1.4: Amphibian metamorphosis is a nature’s paradigm of physiologic tissue 
remodeling in which a fine balance between cell proliferation, apoptosis and cell 
differentiation exists. This gene programming is dependent on TH hormone. The 
same molecule depending on the expression of TR receptors can have different 
biologic effects. Thus, un-liganded TR α1 receptor is associated with proliferating 
cells which are in undifferentiated state (pre-metamorphosis). Liganded TR α1 is 
associated with inhibition of proliferation and cell differentiation (metamorphosis 
period). (Slack et al., 2007). These developmental mechanisms are evolutionary 
conserved in mammals and re-emerge in disease states. (Taken from Mourouzis et al., 
2011). 
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1.7. Thyroid hormone: metabolism and transport  
The major biologically active TH is 3, 3’, 5-triiodothyronine (T3), which is generated 
from thyroxine T4 by the deiodinating enzymes D1 and D2 (Bianco and Kim, 2006; 
Heuer, et al., 2007; Visser et al., 2007). The deiodinase D3 inactivates T4 to 3, 3’, 5’-
triidothyronine (rT3) and T3 to 3, 3’-diidothyronine (T2) (Figure 1.5) (Visser et al., 
2007). Enzymatic activity of D3 is especially high during fetal and neonatal 
development, suggesting that it might act as a scavenger to prevent a premature 
thyroid-hormone-induced differentiation of neural cells (Heuer, et al., 2007).  
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Figure 1.5: Diagram showing the mechanism of cellular action of Thyroid hormone. 
(Taken from Americar Society for Clinical Pathology, 2011). 
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Deiodinases are membrane – associated enzymes, the catalytic center of which is 
located intracellularly. Consequently, thyroid hormone has to enter the cells to be 
metabolized and to interact with its receptors (Heuer, et al., 2007). TH metabolism 
and action require transport of the hormone from extracellular compartments (e.g. the 
bloodstream) across the plasma membrane. Based on their lipophilic nature, it was 
assumed previously that translocation of iodothyronines across the lipid bilayer of cell 
membranes occurred by diffusion. However, experimental evidence over the last three 
decades and clinical studies in recent years show clearly that TH traverses the cell 
membrane mainly through transporters (Hennemann et al., 2001; Abe et al., 2002; 
Jansen et al., 2005; Friesema et al., 2006; Heuer et al., 2007; Visser et al., 2007). 
Several studies have demonstrated that TH uptake has different characteristics in 
different cell types, with regard to ligand specificity, energy (ATP) dependence, Na
+
 
dependence and interactions with a variety compounds (Hennemann et al., 2001; 
Visser et al., 2007). This suggested that TH uptake might be facilitated by different 
types of transporters and that was lately confirmed by the molecular identification of 
TH transporting proteins (Jansen et al., 2005). These transporting proteins include the 
Na
+
taurocholate cotransporting polypeptide (Friesema et al., 1999), fatty acid 
transolcase (van der Putten et al., 2003), multidrug resistance-associated proteins 
(Mitchell et al., 2005), amino acid transporters (Taylor and Ritchie, 2007) and 
members of the organic anion transporting polypeptide (OATP) family (Hagenbuch, 
2007) and monocarboxylate transporter (MCT) family (Visser et al., 2007).  
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1.7.1. Thyroid hormone: cellular action  
1.7.1.1. Genomic action- thyroid hormone receptors 
In 1986, the Molecular cloning of cDNA for thyroid hormone receptors (TRs) led to 
the identification of two TR genes, α and β located on human chromosomes 17 and 3, 
respectively (Weinberger et al., 1986; Sap et al., 1986). Since the first detection of 
thyroid receptors, five major TR isoforms, derived from alternative splicing of the 
primary transcripts of two TR genes have been identified (Cheng, 2003). The thyroid 
receptors belong to a large family of nuclear receptors including steroid hormone, 
retinoic acid, vitamin D and orphan receptors. TRα1, β1, β2 and β3 differ in the 
length and amino acid sequence at the terminal A/B domain, but bind thyroid 
hormone (T3) with high affinity to mediate gene regulatory activity (Cheng, 2003). 
On the other hand the fourth isoform, TRα2, which differs from other isoforms in the 
C-terminus, does not bind T3 and the precise function has not been clarified. These 
receptors like the other nuclear receptors have an amino-terminal A/B domain, a 
central binding domain, and a carboxyl - terminal ligand binding domain while the 
amino- and carboxyl- terminal domains contain activations functions I and II 
respectively that are important for transcriptional activation (Cheng 2000; Yen, 2001; 
Harvey and Williams, 2002). The expressions of TR isoforms is tissue – dependent 
and is developmentally regulated (Cheng, 2000; Yen, 2001). 
The transcriptional activity of TR depends not only on T3, but also on the type of 
thyroid hormone response elements (TREs) on the promoters of T3-target genes. The 
C-terminal region of the ligand binding domain contains multiple contact surfaces that 
are important for dimerization with its partners, the retinoid X receptor, and for 
interactions with co-receptors and co-activators (Cheng, 2000; Yen, 2001; McKenna  
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and O’Malley, 2002; Harvey and Williams, 2002). In the absence of T3, TRs via their 
interacting surfaces associate with co-repressors to act as silencers of transcription 
(Cheng, 2000; Yen, 2001; McKenna and O’Malley, 2002; Harvey and Williams, 
2002).  
 
1.7.1.2. Non genomic action of Thyroid hormone 
T4 can exert several of its non genomic actions without interaction of the hormone 
with the nuclear thyroid hormone receptor, TRβ1, instead it is initiated its effect on 
the plasma membrane receptor via integrin αvβ3 (Davis et al., 2006). The interaction 
of T4 with G-protein-coupled membrane receptor leads to a rapid serine 
phosphorylation of nuclear TRs. Davis et al., (2000) proposed a model for cell surface 
mediated non-genomic actions of TH which involves mitogen activated protein 
kinases (MAPKs) and PI3-kinase signalling cascades. T4 binds on cell surface within 
a time period of 10-30 min, activates Ras, Raf1, MEK and PKC, resulting in tyrosine 
phosphorylation, activation and translocation of MAPKs, which in turn phosphorylate 
a serine residue in the second zinc finger of TR. The nuclear MAPKs/TR complex 
may also bind and phosphorylate p53 and regulate its transcriptional activity (Shih, et 
al., 2001). In a parallel pathway, T4 –activated MEK phosphorylates tyrosine residues 
in STAT1 and STAT3 (signal transducers and activators of transcription) resulting in 
their nuclear translocation, further serine phosphorylation by MAPK and activation of 
gene transcription. Thus, non genomic actions of TH may influence gene transcription 
by at least three distinct pathways STATs, p53 and TRs. 
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T3 also exerts non genomic action via its cytosolic TR α1 receptor. This newly 
discovered non genomic mechanism is of physiologic relevance in acute response to 
stress and mediates TH reparative effect (Pantos et al., 2011) (Figure 1.6). 
 
 
Figure 1.6: Schematic diagram showing the genomic and non genomic actions of TH 
(T4, T3). (Taken from Cheng et al, 2010).  
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1.7.2. Novel thyroid hormone signaling  
 
Recent research has identified that TH regulate novel thyroid hormone signalling 
which may be relevant for tissue repair after injury. Thus, studies in cardiac cell based 
models and animal models of ischemic injury have shown that TH can up regulate 
important molecules involved in tissue differentiation which are of relevance in tissue 
repair (Figure 1.7). 
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Figure 1.7: Schematic diagram showing how TH can alter cellular response to (A) 
non-stress and (B) stress by regulating novel intracellular signaling. (Taken from 
Pantos et al., 2010). 
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1.7.3 Thyroid hormone and tissue differentiation  
 
The role of TH as developmental signal has been demonstrated in several studies with 
Xenopus laevis to be an ideal system for ascertaining the developmental roles of TH 
and its receptors (Slack et al., 2008). Interestingly, this system reveals that regulation 
of TH/TR axis can allow the same simple molecule TH to induce completely opposite 
morphological responses in distinct tissues. In this context (Figure 1.8), TRα seems to 
play an important physiological role due to its dual function (liganded vs unliganded 
state). Thus, at early developmental stages in which TH is low, TRα receptor is highly 
expressed and at its unliganded state acts as a repressor of TH positive regulated 
genes and prevents precocious metamorphosis (Sato et al., 2007). At later stages, the 
rise in TH levels results in the conversion of the unliganded to the liganded TRα state 
and triggers cell differentiation and completes metamorphosis (Furlow and Neff, 
2006). Similarly, in mammals, during fetal life, TRα1 is increased while TH levels 
remain low and decrease after birth with the rising of the circulating TH (White et al., 
2001).  
Based on this evidence, subsequent studies using mammal cell based-models have 
shown that this developmental programme has been conserved in mammals. Thus, in 
the embryonic heart derived cell line (H9c2), which has been used to model aspects of 
cardiac differentiation in vitro,  TH was shown to be critical in this process (van der 
Heide et al., 2007; van der Putten et al., 2002). In fact, intracellular T4 and T3 
increase during the progression of cell differentiation with a concomitant increase in 
the expression of TRα1 and this response could be  prevented by pharmacological 
inhibition of thyroid hormone binding to TRα1 (Meischl et al., 2008; Pantos et al., 
2008c; van der Heide et al., 2007; van der Putten et al., 2002). The potential role of   
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TRα1 in cell differentiation/de-differentiation process has been further documented in 
transfection studies using neonatal cardiomyocytes (Figure 1.8). Thus, neonatal 
cardiac cells overexpressing TRα1 and treated with TH were able to differentiate into 
adult cardiac cells (Kinugawa et al., 2005). On the contrary, untreated cardiomyocytes 
remained undifferentiated and this response was characterized by cell growth with a 
foetal pattern of myosin heavy chain (MHC) isoform expression (Kinugawa et al., 
2005). This novel action was shown to be a unique feature of TRα1 receptor. Along 
this line, TH was shown to stop proliferation and promote differentiation in fetal 
bovine cardiomyocytes (Figure 1.8 and 1.9). Interestingly, this unique effect was 
shown to be achieved in nearly normal T3 concentrations and is mediated via T3 
action on cyclin D1 and p21 (Figure 1.10) (Chattergoon et al., 2011). 
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Figure 1.8: Cellular model of cardiac embryonic cell differentiation. (A) During fetal 
development, (B) cell proliferation and (C) apoptosis prevails. Apoptosis is a 
physiologic brake of growth. This process is inhibited during the transition to cell 
differentiation. Interestingly, in adult life, re-emergence of the fetal state occurs in 
disease. (Taken from Walsh et al., 1997). 
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Figure 1.9: Cardiac myoblast differentiation is dependent on TH. Blockade of TRα1 
receptor by TRα1 inhibitor (DbD) delays this process. (Taken from Pantos et al, 
2008). 
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Figure 1.10: TH stops proliferation in (A) fetal bovine left ventricle cardiomyocytes. 
This effect is mediated via T3 action on (B) cyclin D1 and (C) p21. (Taken from 
Chattergoon et al., 2011). 
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1.7.4. Thyroid hormone (TH) and brain development   
Thyroid hormone is essential for the proper development of numerous tissues, notably 
the brain. As an important target tissue of thyroid hormone action, the mammalian 
CNS is highly dependent on proper thyroid hormone supply. In rodents, it was found 
that deprivation of thyroid hormone during critical periods of brain development 
affects processes such as neuronal migration, outgrowth and differentiation, 
synaptogenesis, myelination and glial cell proliferation (Oppenheimer and Schwartz, 
1997; Anderson et al., 2003). Normal timing of oligodendrocyte development 
depends on thyroid hormone receptor alpha 1 (TRα1) (Billon et al., 2002) (Figure 
1.11). 
If thyroid hormone is to act in the brain, several transport processes have to take 
place. Firstly the hormone has to enter the brain and that occurs either via blood-brain 
barrier or the choroid plexus-cerebrospinal fluid (CSF) barrier (Heuer, et al., 2007). 
The entry of T4 and T3 via the blood-brain barrier appears to be the preferred route 
for the distribution of thyroid hormone in the brain, whereas the uptake via choroid 
plexus –CSF barrier is thought to be necessary to provide circumventricular areas 
with sufficient amounts of thyroid hormone (Dratman, et al., 1991). After passing one 
of these barriers, T4 has to be taken up by astrocytes for further activation and finally 
T3 has to enter neuronal cells, which not only express TRs but also participate in the 
inactivation of T4 and T3 by expressing D3 (Heuer, 2003). 
In the brain, de-iodinase D2, an enzyme expressed in astrocytes, tancycytes and in 
some sensory neurons, is responsible for converting T4 to T3 (Guadano-Ferraz, et al., 
1997; Guadano-Ferraz, et al., 1999; Heuer, et al., 2007). Inactivation of T4 and T3  
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can also take place within the brain is catalysed by the neuronally localized 
deiodinase D3 (Tu, et al., 1999; Heuer, et al., 2007) 
Most remarkably, the activity of both D2 and D3 in the brain is profoundly affected 
by the thyroidal state of this tissue. In the presence of low levels of thyroid hormone, 
D2 activities are strongly upregulated and D3 activities are markedly decreased 
(Burmeister et al., 1997; Friedrichsen, et al., 2003). These alterations in local thyroid 
hormone metabolism have been suggested to represent a compensatory mechanism 
not only to cope with fluctuations in the circulating thyroid hormone levels but also to 
protect the brain from the detrimental effects of hypothyroidism as well as 
hyperthyroidism (Calvo et al., 1990; Guadano-Ferraz et al., 1999; Heuer et al., 2007). 
The local conversion of T4 to T3 by D2 in astrocytes was estimated to produce as 
much as 80% of the T3 bound to the nuclear receptors in the adult rat brain, indicating 
that astrocytes are critically involved in regulating the amount of T3 available for 
neuronal uptake (Heuer, 2003). 
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Figure 1.11: Oligodendrocyte development in the optic nerve is impaired in TRα1 -/- 
mice, but this only occurs at postnatal age of days 7 to 14. (Taken from Billon et al., 
2002).  
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1.7.5. Changes of thyroid hormone signalling in disease: a response of 
physiologic relevance  
It has long been recognized that circulating thyroid hormone in plasma are altered in 
acute and chronic illnesses (Pantos et al., 2010). The physiological relevance of this 
response, known as euthyroid sick syndrome remains largely unknown. However, 
accumulating clinical evidence shows that low T3 levels in plasma are correlated with 
poor outcome of the disease (Koenig et al., 2008). 
 
1.7.6. Changes in thyroid hormone signalling in heart diseases  
The importance of TH in the cause and progression of the disease has mostly been 
studied in heart diseases. Thus, circulating T3 levels have been associated with the 
severity of cardiac dysfunction in heart failure patients and the recovery of cardiac 
function after myocardial infarction. Moreover, low T3 levels appear to increase 
mortality (Pantos et al., 2010). Accordingly, in animal models of pathological growth 
and heart failure caused by ischemia, a distinct pattern of TRα1 expression occurs. In 
fact, a re-expression of TRα1 was shown to occur during the development of 
pathological growth. Interestingly, TH treatment converted the pathological growth to 
physiological growth and prevented heart failure (Pantos et al., 2010). 
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1.7.7. Changes in thyroid hormone signalling in cancer 
The interest for potential role of thyroid hormone signalling in cancer came from the 
recognition that TRα1 is the cellular counterpart of the retroviral v-erbA which is 
involved in the neoplastic transformation leading to acute erythroleukemia and 
sarcomas (Sap, et al., 1986; Thormeyer and Baniahmad, 1999). V-erbA itself has a 
weak oncogenic activity but augments the transformation activity of other oncoprotein 
(Cheng, 2003). V-erbA competes with TR for binding to TREs and interferes with the 
normal transcriptional activity of liganded-TR on several promoters (Yen et al., 1994; 
Chen and Privalsky, 1993). Bearing that in mind, the v-erbA oncoprotein is thought to 
repress constitutively, through its dominant negative activity, a certain set of genes 
that prevent cellular transformation (Cheng, 2003). 
Along this line, cyclin D1 and p53 were shown to physically interact with TRβ1 
(Cheng, 2003). p53 was shown to interact with TRβ1 in vitro and in cultured cells,  
resulting in the repression of the transcriptional activity of TRβ1 (Bhat, et al., 1997). 
Cyclin D1 associates with C-terminal region of the ligand-binding domain of TRβ1 in 
vitro and in vivo and acts to repress the transcriptional activity of TRβ1, α1 and β2 
(Lin et al., 2002). 
Aberrant expression of TR has been found in breast cancer (Li et al., 2002; Silva, et 
al., 2002; Ferreira, 2006). Furthermore, in a study by Li et al. (2002), a variable 
degree of hypermethylation was observed in 11 cases of breast cancer. In addition, 
silencing of the TRβ gene by hypermethylation and concurrent reduction of TRβ1 
transcripts were demonstrated in several breast cancer cell lines (Cheng, 2003). Silva 
et al., (2002) demonstrated alterations in mRNA and protein levels of TRs in 70 
sporadic breast cancers. Truncated mRNA was found in six patients and in three   
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transcripts was found the same breaking point. Although there was no significant 
correlation between the TRβ1 alterations and clinical features, there was a tendency 
toward association of mutations and onset of cancer in early age (Silva et al., 2002; 
Cheng, 2003). Concluding from all these findings, it could be suggested that the TRβ 
gene may function as tumour suppressor in a subset of breast cancers (Cheng et al., 
2003). 
In liver cancer, Lin et al., (1999) showed that truncated TRα1 and TRβ1 cDNA was 
present in 53% of human haepatocellular carcinomas. Furthermore, somatic point 
mutations of TRα1 and TRβ1 were found in 65% and 76% of the haepatocellular 
carcinomas, respectively. Moreover, multiple point mutations were observed in 
mutated TRs (Lin et al., 1999). Mutated TRs were observed in other studies of 
haepatocellular carcinomas also, demonstrating that these TRs have no normal T3 
binding and transcriptional activities (Lin et al., 1996; Lin et al., 1997). However, in 
these studies it was not clear how the dominantly negative TR mutants led to 
haepatocellular carcinomas. 
Aberrant expression of TRα and TRβ genes has found in renal cell carcinomas 
(Puzianowska – Kuznicka et al., 2000). Puzianowska – Kuznicka et al. (2000) showed 
that the expression of both TRα1 and TRα2 mRNAs was reduced, whereas the TRβ1 
mRNA was over expressed in 30% and reduced significantly in 70% of tumours 
examined. In  22 cases of renal cells carcinomas, mutations of TRβ1 were  found in 
seven cases (32%), mutations of TRα1 cDNAs in three cases (14%), and  in two cases 
TRβ1 cDNAs were mutated (Kamiya et al., 2002). Furthermore, five TRβ1 and three 
TRα1 cDNAs had two to three mutations (Kamiya et al., 2002). Most of these 
mutations were localized in the hormone binding domain that leads to loss of T3 
binding activity and / or impairment in binding to TREs (Kamiya, et al., 2002).  
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1.7.8. Thyroid hormone as potential treatment for cancer  
The potential beneficial effect of TH was shown more than a century ago in patients 
with breast cancer treated with thyroid extracts. (Beatson et al., 1896) However, 
primary hypothyroidism has also been associated with a reduced incidence of primary 
breast carcinoma (Cristofanilli et al., 2005). Hypothyroidism though may have a dual 
effect on tumourigenesis; in animal models of induced tumour growth by 
haepatocarcinoma and breast cancer cells, tumour growth was slower in hypothyroid 
mice but was aggressive (undifferentiated) and invasive (increased metastasis). This 
was shown to be due to the decrease in cell proliferation, induction of cell 
dedifferentiation and changes in the extracellular matrix (Martinez-Iglesias 2009). 
Further to this controversial results, hypothyroidism has been shown to be a risk 
factor in patients with liver cancer (Reddy et al., 2007) and in animals, T3 treatment 
induced rapid regression of carcinogen induced hepatic nodules and reduced the 
incidence of hepatocarcinoma and lung metastasis ( Ledda –Columbano et al., 2003; 
Ledda –Columbano et al., 1999; Perra et al., 2008). 
Recent studies have explored the potential role of thyroid hormone receptors in 
cancer. Thus, TRs are shown to control tumourigenesis through distinct mechanisms.  
Expression of TRβ1 was shown to totally tumour formation by ras-transformed cells 
in nude mice, even under hypothyroid conditions. On the other hand, tumour 
formation was reduced in euthyroid mice inoculated with cells expressing ras 
oncogene and TRα1, but all hypothyroid animals developed tumours, although 
tumour appearance was significantly delayed (Figure 1.12). These results are 
consistent with the ligand-dependent antitransforming activity of this receptor isoform 
and indicate that TRα1 could only have tumour suppressor activity under euthyroid 
conditions. (in liganded state).  
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Figure 1.12: Overexpression of unliganded TRα1 (in the case of induced 
hypothyroidism) increases cancer growth compared to liganded TRα1 (as in euthyroid 
mice). (A) This pattern closely resembles that observed in pathologic cardiac 
growth,(B/C) indicating a potential role of TRα1 in cancer and heart disease. (Taken 
from Garcia-Silva and Aranda, 2004). 
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1.7.8.1. Changes in thyroid hormone signalling in brain cancer 
Alterations in the expression of TRs in human brain tumours have been found mainly 
in pituitary tumours and meningiomas. (Margassi, et al., 1993; Wang, et al., 1995; 
Gonzalez-Sancho, et al., 2003; Wang, et al., 2003; Monden, et al., 2006). Wang et al., 
(1995) demonstrated that human TRs were differentially expressed in human pituitary 
tumour cells. Furthermore, reduced expression of TRs in thyrotropin – secreting 
pituitary tumours may also lead to a defective negative feedback of the thyroid 
hormone on thyrotropin production and this contribute to uncontrolled tumour growth 
(Gittoes et al., 1998). Hwang et al., (2008), compared TR expression between low 
grade (WHO grade II) and high grade (WHO grade III and IV) astrocytomas and 
showed that the frequency of either TRα1 or TRα2 expression was significantly 
decreased with the grade of malignancy. However, the frequency of TRβ1 expression 
significantly increased with the grade of malignancy astrocytomas (Hwang, et al., 
2008). 
 
1.7.9. Thyroid hormone treatment  
The potential effects of T3 on cell proliferation and differentiation were shown in 
neuro-2a cells transfected with TRβ1. T3 (at concentrations ranging from 3 nM to 300 
nM) blocked proliferation in G0/Gi and induced differentiation as indicated by 
increase in the number of perisomatal filopodia-like neuritis and achetylcholinestarase 
staining. This effect was evident after 24h and peaked at 48h. Interestingly, T3 had no 
effect on non transfected neuro-2a cells in which TRα2 receptor expression was 
dominant inhibiting TRα1 which was less expressed (Lebel et al., 1994). Taken these 
data together, it appears that T3, even at low concentrations (which are of physiologic   
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and therapeutic relevance) can inhibit proliferation and differentiation via its genomic 
action.  This effect may be lost in the case the expression of TRs is altered.  The 
potential of T3 to induce cell necrosis has not been explored. 
Contrary to its genomic effect, TH was shown rather to promote proliferation via a 
non genomic acute action (Davis et al., 2006, Lin et al., 2009). Interestingly, this 
action was shown to be initiated at the cellular membrane and thus, T4 was more 
potent growth inducer than T3. In fact, a proliferative effect was hardly seen with T3 
at nearly physiologic concentrations (~1 nM). This effect was shown in several cell 
lines including C6, F98, GL261 and U87MG (Davis et al., 2006; Lin et al., 2009). 
These data probably point out that TH transient effect may proliferation which though 
may be avoided by low T3 concentrations. 
 
1.8. Working hypothesis 
Based on the evidence above, it appears that the effects of TH on cell differentiation 
may be of relevance in cancer treatment. Preliminary experimental studies on brain 
malignances show a potential role of thyroid hormone as a novel treatment. This 
prompts for further studies in order to better understand the effects of TH on the 
balance of cell proliferation, cell differentiation and cell necrosis and the potential 
underlying mechanisms. 
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1.9. Aims of the study 
The main aim of this study was to investigate the potential anti-cancer effects of 
thyroid hormone on glioma tumour cell lines. 
The specific aims of the present study are: 
 
 To confirm a TH differentiating action in an established model of  cell  
differentiation / de-differentiation such as  neonatal cardiomyocytes treated  
with growth factors 
 To investigate the effects thyroid hormone on the morphology of glioma cells. 
 To determine the effect thyroid hormone has on the cell growth of glioma cell 
lines. 
 To determine the effects of thyroid hormone on proliferation of glioma cell 
lines. 
 To determine the effects of thyroid hormone on apoptosis in glioma cell lines. 
 To determine the effects of thyroid hormone on cell injury. 
 To investigate the potential effect of thyroid hormone in relation to the degree 
of aggressiveness and altered expression of thyroid hormones. 
 To investigate the pattern of growth kinase signalling which is potentially 
implicated in the thyroid hormone effect on glioma cell lines. 
 To analyze the data and write up the PhD thesis.   
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Chapter Two 
 
      Materials and Methods  
74 
 
Materials 
1321N1: grade II astrocytomas 
Acrylamide 
Amphotericin B 
Anti-mouse antibody 
Anti-rabbit HRP antibody 
Aprotinin 
Ascorbic acid 
BrdU: labelling reagent 
Bromophenol blue 
BSA: Bovine serum albumin 
Cardiomyocytes 
CO2: carbon dioxide 
Digital camera (Axio Cam) 
DMEM: Dulbeccos modified eagles medium 
DMSO: freezing medium 
DTT: Dithiothreitol 
EDTA: Ethylenediaminetetraacetic acid  
Ethanol  
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F10 medium 
FBS: fetal bovine serum 
Glycerol 
Glysin 
HEPES: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
Horse serum 
KCl: potassium chloride 
LDH: lactate dehydrogenase 
Leupeptin 
L-glutamine 
Lumiglo reagent 
MEM: essential minimum eagle medium 
Mercaptoethanol  
Mercaptoethanol 
Methanol 
MgCl2: Magnesium chloride 
NaCl: Sodium chloride 
Neubauer hematocytometer 
Nitrocellulose membrane  
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NP-40: nonyl phenoxypolyethoxylethanol 
PBS: phosphate buffer solution 
Penicillin 
Peroxidase anti mouse IgG2a 
PMSF: phenylmethylsulfonyl fluoride 
SDS: sodium dodecyl sulfate 
Sodium bicarbonate 
Sodium pyruvate 
Streptomycin 
Transferin/ selenium 
Tris base 
Tris-HCL 
Trypsin 
TUNNEL staining in situ cell death detection kit 
U87-MG: grade IV glioblastomas 
Zeiss microscope 
β-MHC: slow muscle myosin  
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2.1. Studies on cardiac cell-based models 
 
2.1.1. Cell culture  
Rats were handled in accordance with the Guide for the Care and Use of Laboratory 
Animals published by the US National Institutes of Health (NIH Publication No 85-
23, revised 1996). Neonatal rat cardiomyocyte cultures were prepared as previously 
described (Detillieux et al., 1999) with some slight modifications. Ventricles from 
Wistar rat pups (0-48 h after birth) were dissected, and the cells were dissociated in a 
spinner flask using a combination of collagenase (740 u/digestion Worthington 
Biochemicals, NJ), trypsin (370 u/digestion Worthington Biochemicals, NJ), Dnase I 
(2880 u/digestion Worthington Biochemicals, NJ).  Myocytes were separated from 
non-muscle cells on a discontinuous Percoll gradient and plated at a density of 45000 
cells/cm
2
 for geometry-shape measurements, immunocytochemistry and protein 
content measurement. Cells were initially plated in F10 medium (Gibco) containing 
10% Fetal Bovine Serum (Hyclone), 10% horse serum (Gibco) and antibiotics 
(100u/ml penicillin and streptomycin, Gibco) for the first 18-22 hours and then the 
culture medium was replaced with serum-free medium containing 10 μg/ml insulin, 
10 μg/ml transferin/selenium, 0.2% BSA and 20 μg/ml ascorbic acid.  
 
2.1.2. Measurement of Neonatal Cardiomyocytes Axes and Cell Size 
Iimages of neonatal cardiomyocytes were acquired using a digital camera (AxioCam 
MRC with AxioVision software) incorporated on a Zeiss microscope (Axiovert 25). 
Cells images were projected in a computer and a mouse was used to draw around the 
perimeter of each cell or to measure the major (a) and minor (b) axis. AlphaScan  
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Image analysis was used to calculate the planimetric area and the axes length. A sum 
of 100 to 200 cells from 5 different dishes was measured in each group.  
 
2.1.3. Determination of cardiomyocyte growth (Cellular Protein 
Content) 
Total protein content of myocytes was measured as previously described (Lai et al., 
1996) with some modifications. Cells of all groups were plated at a density of 45000 
cells/cm
2
 and cultured for 5 days. The cells were washed twice with PBS and 200 μl 
Trypsin 0.25% was added to each well and incubated at 37
0
C until the cells detached. 
A solution of 10% FBS in PBS was added to each well to stop the reaction. The cells 
were harvested and a small fraction was used for determination of the cell number 
using a Neubauer hematocytometer. Cells were then collected by centrifugation and 
incubated with 100 μl lysis buffer (250mM Tris-HCL, 4% SDS, 10% glycerol pH 6.8) 
at 4
0
C overnight. This mixture was then warmed at 37
0
C, and protein concentration 
was determined using the DC protein assay (Bio-Rad) based on the Lowry method 
(Lowry et al., 1953). Protein contents were normalized to the cell count. Twenty 
samples (dishes) from each group were used for this analysis. 
 
2.1.4. Myosin Heavy Chain (MHC) Isoform Protein Analysis 
Cells (plated at a concentration of 100.000 cells/cm
2
) were washed twice with PBS, 
scraped into 100 μl lysis buffer (250 mM Tris-HCL, 4% SDS, 10 % glycerol pH 6.8) 
and boiled for 5 min at 100
0
C. Protein concentration was determined by the DC 
protein assay (Bio-Rad) based on the Lowry assay and the originally prepared 
samples were diluted 15 fold with Laemmli sample buffer containing 5% 2-
mercaptoethanol. The composition and preparation of the gels was carried out as   
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previously described (Pantos et al., 2008; Reiser et al., 2006). The stacking and 
separating gels consisted of 4 and 8% acrylamide (wt/vol) respectively, with Acryl: 
bis-Acryl in the ratio of 50:1. The stacking and separating gels contained 5% (vol/vol) 
glycerol. The upper running buffer consisted of 0.1 M Tris (base), 150 mM glycine, 
0.1% sodium dodecyl sulfate (SDS) and 2-mercaptoethanol at a final concentration of 
10 mM. The lower running buffer consisted of 0.05 M Tris (base), 75 mM glycine and 
0.05% SDS. The gels were run in Biorad Protean II xi electrophoresis unit at a 
constant voltage of 240 V for 21 h at 8
 o
C. The gels were fixed and silver-stained 
(Biorad silver stain kit). Gels were scanned and quantified using the AlphaScan 
Imaging Densitometer (Alpha Innotech Corporation, USA). Four samples (dishes) 
from each group were used for this analysis. 
 
2.1.5. Immunocytochemistry 
Cardiomyocytes from all groups cultured in collagen-coated (collagen, Type I, 
Upstate) glass cover slides (Fisher Scientific), were  fixed with 4% paraformaldehyde 
(Sigma) for 15 min at 4
0
C and permeabilised with 0.1 % Triton-X/PBS for 15 min at 
4
0
C. Subsequently, the cells were incubated with fluorescent phallotoxin (Molecular 
Probes) in 1%BSA/PBS for 20 min at room temperature for staining of actin filaments. 
After each step, cells were washed three times with PBS. For immunocytochemical 
staining of myosin, cells were incubated with the slow-muscle myosin (β-MHC) 
antibody (Chemicon, dilution 1:1000) for 1.5 hour at room temperature and then 
treated with the goat anti-mouse IgG (Alexa-Fluor, Chemicon, dilution 1:1000) in 
1%BSA/PBS at room temperature. After each step, cells were washed three times with 
PBS.  
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Slides were mounted and examined by fluorescence phase-contrast microscopy (Zeiss 
Axiovert). 
 
2.1.6. Experimental protocol  
Cells were serum-starved for 24 hours before the initiation of the experimental 
protocol. These cells were remained undifferentiated.  Further dedifferentiation was 
induced by the use of phenylephrine (PE), an α1 adrenergic agonist at a dose of 20 μΜ 
for 5 days as previously described (Kinugawa et al., 2001) T3, at 100 nM was used to 
differentiate undifferentiated and dedifferentiated cells.  This dose is at the range of 
doses that have been previously used in this experimental setting (Kinugawa et al., 
2001; Gosteli-Peter et al., 2003). 
 
 The following experimental studies were performed: 
 
Study 1. Assessment of cell growth, cell morphology,   myosin expression in 
neonatal cardiomyocytes which remained untreated for 5 days (control group, 
CONT, n=6) and cardiomyocytes dedifferentiated with phenylephrine (PE), an 
alpha adrenergic receptor agonist, 20 μM for 5 days (PE group, n=6).  
 
Study 2. Assessment of cell growth, cell morphology myosin expression in 
undifferentiated neonatal cardiomyocytes treated with T3 100 nM for 5 days 
(T3 group, n=6).  
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Study 3. Assessment of cell growth, cell morphology myosin expression in 
dedifferentiated cardiomyocytes treated with phenylephrine 20 μM and T3 100 
nM for 5 days (PE-T3 group, n=6). 
 
2.2. Studies on Glioma cell lines 
 
2.2.1. Cell Culture 
Cell line 1321N1, an astrocytoma grade II, and U87MG a glioblastoma grade IV were 
used in this study. Glioma cell line U87MG was obtained from the American Type 
Culture Collection (ATCC) (Manassas, VA) and glioma cell line 1321N1 was 
obtained from the European Collection of Cell Culture (ECACC) (Salisbury, 
Wiltshire, UK). All cell lines were maintained in 150 cm² cell culture flasks 
(CORNING). 
U87MG was maintained in Essential Minimum Eagle Medium (MEM) with Earle’s 
salts supplemented with 10% fetal bovine serum (GIBCO), 1 mM sodium pyruvate, 
streptomycin and penicillin (5% v/v), 0.1 mM non-essential amino acids, 2 mM L-
glutamine and amphotericin B (5% v/v).  
1321N1 was maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) with 
glucose and sodium bicarbonate supplemented with 10% FBS, 2 mM L-glutamine, 
5% penicillin and streptomycin and 5% amphotericin B. 
All cell lines were maintained in a 37º C humidified incubator with 5% CO2. For all 
experiments, each of the glioma cell lines were used between passages 20-30. Once 
cells were 70-80% confluent they were trypsinized using 1X (1x 2.5 g porcine trypsin 
per litre in Hanks’ Balanced Salt solution, Sigma) Trypsin. Cells were settled for 24   
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hours in stripped medium (using charcoal FBS, GIBCO) before the initiation of 
treatment. 
 
2.2.2. Subculture 
Once cells were 70- 80% confluent, they were trypsinized using 1X Trypsin and 
incubated at 37° C for 5-10 minutes. For the 150 cm² flasks, 3 mL of trypsin was 
added. After 5 min, the flasks were taken from the incubator and viewed under an 
inverted light microscope to see if the cells had detached. If not, the flasks were 
placed back into the incubator and checked again every few minutes until the cells 
had fully detached. Once detached, cell medium was added to neutralize the trypsin 
and prevent causing any damage to the cell membranes. For each 1 mL of trypsin, at 
least 1 mL of medium was added to the flask to neutralize the trypsin reaction. 
To re-culture the cells, the cell suspension was added to new flasks containing fresh, 
warm medium at approximately 2-4 x 10
4
 cells/ cm
2
 depending on the cell line. New 
flasks were then placed back into the incubator and left for 24 hours to attach. After 
24 hours, the flasks were viewed under a light microscope to ensure they had attached 
healthily and were proliferating. 
 
2.2.3. Cell freezing 
During cell freezing, the cells were tryspinized and counted as previously described 
above. The cells were then resuspended in cell freezing medium (medium + 0.5% 
DMSO) at a cell concentration of 1X10
6
 cells per mL, aliquoted in to cryovials, and 
put into a ‘Mr Frosty’ at room temperature. The ‘Mr Frosty’ was immersed in 
isopropanol, which cooled the cells, and placed in a -80° C freezer; this method 
caused the cells to be cooled at -1° C per minute. The cryovials were left overnight at   
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-80° C and then immersed in liquid nitrogen the following day, until required for sub-
culture. 
 
2.2.4. Culturing cells from frozen 
Cryovials were taken from liquid nitrogen and quickly immersed in a 37° C bath to 
defrost. Once defrosted, the vials were wiped with a tissue, doused in 70% ethanol, 
and the cells were then placed in a 150 cm
2
 flask containing warm fresh medium and 
placed into an incubator overnight. The following day, the medium was changed and 
fresh medium was added to remove as much of the cryoprotectant, DMSO, as 
possible. 
 
2.2.5. Cell Assays 
2.2.5.1 Cell counting 
Once the cells were tryspinized and the trypsin was neutralized using cell media, 1 
mL of cell/medium mix was taken from the flask and placed into a sterile Eppendorf 
tube. Using a haemocytometer (as displayed in figure 2.1), a cover slip was attached 
using a small amount of moisture, such as an exhaled breath, onto the slide. 
Approximately, 20 µL of the cell suspension was pipetted on to the slide and the slide 
viewed under a light microscope, under 20X magnification and the cells counted 
within the squares (figure 2.1). All cells were counted within a 4x4 grid (figure 2.1) 
and then a further two grids were counted to obtain an average. 
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Figure 2.1: Diagram presenting the methods involved in cell counting using the 
Neubauer haemocytometer and cell cover attachment. (Taken from Power point 
presentation). 
 
2.2.5.2. Cell morphology 
Cell morphology was used to assess cell differentiation. Cells were fixed in 
paraformaldehyde solution, before being viewed with an inverted light microscope 
fitted with phase contrast optics. A scale (called a reticule) was built into one eyepiece 
of the light microscope, and was used to measure any planar dimension in a 
microscope field since the ocular can be turned in any direction and the cell can be 
repositioned with the stage manipulators. To measure the length of a cell the number   
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of ocular division spanned by the object had to be noted. Finally multiply by the 
conversion factor for the magnification used. Five random fields, each containing no 
more than 50 cells, were examined in each well and the total numbers of cells as well 
as the total number of projections that were greater than two cell body diameters in 
length were recorded. Data were derived from approximately 100 cells in each group. 
Cell morphology could not be reliably assessed at 96 hours due to more than 80% 
confluence. 
 
2.2.5.3. Cell proliferation 
For determining cell proliferation, BrdU labelling reagent (RPN20 kit, GE Healthcare, 
Piscataway, NJ) was added to the medium. Cells were incubated for 30 minutes and 
then fixed using 4% paraformaldehyde for 15 minutes. Primary antibody (anti-BrdU 
monoclonal antibody, dilution 1:100) was applied for 1h at room temperature. 
Samples were washed 3 × 5 minutes with PBS. Secondary antibody (peroxidase anti-
mouse IgG2a) was then applied for 30 minutes at room temperature, followed by 
washing 3 × 5 minutes. Finally, BrdU-immunostained cultures were visualized using 
DAB and photographs taken with a digital camera (Zeiss Axiovert) attached to an 
inverted microscope fitted with phase contrast optics. DAB has the ability to stain 
black the nucleus of the cells that are about to proliferate leaving the nucleus of the 
rest of the cells white. BrdU-positive nuclei were counted as a percentage of total 
nuclei. Proliferation data are derived from between 450 to 600 cells measured in each 
group. 
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2.2.5.4. Cell apoptosis 
Apoptotic cell nuclei were assessed by TUNNEL staining using an In Situ Cell Death 
Detection Kit, according to a standard protocol based on the manufacturer’s 
instructions (ROCHE, Cat. No. 11 684 795 910).  Cell cultures were counterstained 
with Hoeschst 33358 (5 μg/ml) which stained the nuclei of all cells. Administration of 
doxorubicin known to induce apoptosis was used as a positive control in order to 
certify the selected method. 
 
2.2.5.5. Cell injury 
Cellular injury was assessed by LDH enzyme release in to the cultured medium. 
Culture medium was collected at the end of the experiment  for the measurement of 
lactate dehydrogenase (LDH) activity (IU/L) using an ELISA kit (Quantichrom LDH 
Kit,DLDH-100, BioAssay Systems, USA). Measurements were performed with a 
Tecan Genios system (wavelength 565 nm). LDH release was expressed in each 
group as a percentage of the non-treated group. 
 
2.2.5.6. Molecular analysis 
After washing twice with PBS, the cells were scraped into 400 μl lysis buffer 
containing 20 mM HEPES, pH 7.9, 10 mM KCl, 1 mM EDTA, 10% glycerol, 0.2% 
NP-40, 0.5 mM DTT, 0.5 mM PMSF, 5 μg/ml aprotinin, 5 μg/ml leupeptin. A small 
quantity of total lysate was kept and the remainder centrifuged at 12000 g for 1 min at 
4
0 
C. The nuclear fraction was prepared by resuspension of the pellet in buffer 
containing 20 mM HEPES, pH 7.9, 0.42 M NaCl, 0.2 mM EDTA, 1.5 mM MgCl2, 
25% glycerol, 0.5 mM DTT, 0.5 mM PMSF, 5 μg/ml aprotinin, 5 μg/ml leupeptin, and 
incubated with agitation for 1 hour at 4
0 
C before centrifugation for 10 min at 12,000g.   
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The resulting supernatants were collected and used for protein analysis of the nuclear 
fraction. Protein concentrations were determined by the BSA assay method. After 
boiling for 5 min (with 4% SDS, 2% mercaptoethanol and 0.004% bromophenol blue) 
a quantity of 15 μg protein from nuclear or total fraction was separated on 7.5% SDS-
PAGE using a Bio-Rad Mini-Protean gel apparatus. For Western blotting, proteins 
were transferred electrophoretically to a nitrocellulose membrane (Hybond ECL) at 
100 V and 4
o 
C, for 1.5 h using Towbin buffer (with 6.06 Tris, 28.8 Glysin, 400 ml 
Methanol and 1300 ml water). Filters were afterwards probed with specific antibodies. 
For Western blotting, membranes with total protein extracts were blocked with 5% 
non-fat milk in TBS-Tween for 60 min and then probed with specific antibodies 
against total and phospho-ERK (Cell Signaling Technology, dilution 1:1000) and total 
and phospho-Akt (Cell Signaling Technology, dilution 1:1000), overnight at 4
0 
C. 
Filters were incubated with appropriate anti-rabbit HRP secondary antibody (Cell 
Signalling, 1:4000, 1h R.T.) and immunoreactivity was detected by enhanced 
chemiluminescence using Lumiglo reagents (New England Biolabs). Immunoblots 
were quantified using the FluorChem HD2 system (Alpha Innotech Corporation, 
14743, Catalina Street, San Leandro, CA).  
 
2.2.5.7. Measurement of thyroid hormone receptors 
After Western blotting, filters were probed with specific antibodies against TRα1 
(Abcam Rabbit polyclonal to TRα1, ab53729, dilution 1:1000, o/n at 40C) and TRβ1 
(Affinity Bioreagents, MA1-216, dilution 1:1000, o/n at 4
0
C). Filters were incubated 
with appropriate anti-mouse (Amersham) or anti-rabbit (Cell Signalling) HRP 
secondary antibodies. Immunoreactivity was detected by enhanced   
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chemiluminescence using Lumiglo reagents (New England Biolabs). 
Chemiluminescence was detected by the image analysis system FluorChem HD2 
(AlphaInnotech Corporation, 14743, Catalina Street, San Leandro, CA) equipped with 
a CCD camera and analysis software. Five samples from each group were loaded on 
the same gel. Ponceau staining was used in order to normalize slight variations in 
protein loading. 
 
2.2.5.8. Construction of Growth Curves 
Growth curves provide important information when changes in cell number are to be 
used as a study end-point. A typical growth curve consists of the lag phase before the 
cells start to grow, the log phase of exponential growth and the plateau phase when 
contact-inhibited cells will cease growing. The lag period lasts usually around 12–24 
hours and allows the cells to recover from trypsinization, reconstruct their 
cytoskeleton, secrete matrix to aid attachment, and spread out on the substrate, 
enabling them to reenter cell cycle. During the log phase the cell population doubles 
over a definable period, known as the doubling time and characteristic for each cell 
line. The rate of growing is calculated during the log phase of growth (Figure 2.2). 
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Figure 2.2: Time course changes in a typical growth curve. Note that maximal growth 
occurred after 7-8 days of culture. Typical of 10 such different experiments. 
 
In order to construct the growth curves serum used in the culture medium for these 
experiments was stripped from steroid hormones in order to keep the untreated cells 
devoid of thyroid hormones. Then, population doubling time and saturation density 
were determined.  
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2.3. Experimental Protocols 
In the present study, T3 was used as chronic treatment since T4 acts on the cell 
membrane and has no genomic long acting effects. Cells deprived of T3 in medium 
were used as controls (0 nM, untreated).  Two doses of T3 were used based on 
previous data (Lebel et al., 1994; Aranda et al., 2004).  Thus, cells were treated with 1 
nM which is a near physiologic dose and clinically relevant. A second dose of 500 nM 
was used as supraphysiological dose. The effects of T3 were assessed in two time 
points; 48 h and 96 h. This was based on the data obtained from the construction of 
growth curves and from previous studies showing that the effect of T3 on cell 
differentiation was peaked at 48h (Lebel et al., 1994). 
 
2.4. Experimental studies  
 
Study 1. Morphological characteristics of glioma cell lines 
Two different cell lines (1321N1 and U87MG) were examined to determine the effect 
of T3 upon their morphology. After the cells had reached confluence, approximately 
17000 cells/mm
2
 cells were placed in a 35 mm petri dish and treated with T3 at doses 
of 0 nM, 1 nM and 500 nM for a period of 12, 24 and 48 hours. Cells were fixed, 
before being viewed under an inverted light microscope fitted with phase contrast 
optics. Five random fields, each containing no more than 50 cells, were examined for 
each of the doses. The number of projections and the ratio of cell length/width of each 
cell were recorded. Data were derived from approximately 100 cells in each group, 
n=8 repeats for each group. 
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Study 2. Cell count of glioma cell lines 
Two different cell lines (1321N1 and U87MG) were examined to determine the effect 
of T3 on the cell number. The cell lines were cultured until reaching a confluence level 
of 80%, and after trypsinisation approximately 17000/mm
2
 cells of each cell line were 
placed in a 60mm petri dish and treated with T3 at doses of 0 nM, 1 nM and 500 nM 
for a period of 12, 24 and 48 hours (n=8 for each dose). Cell number was estimated 
using a light microscope and a Neubauer haemocytometer.  
 
Study 3. Proliferation of glioma cell lines 
The two different cell lines (1321N1 and U87MG) were studied to examine the effect 
of T3 on the cell proliferation. After the cells had reached confluence, approximately 
8500 cells /mm
2
 were placed in a 60 mm petri dish (n=8 for each dose) and treated 
with T3 at the doses of 0 nM, 1 nM and 500 nM for a period of 12, 24 and 48 hours. 
A smaller density of cells were placed in the petri dish for proliferation experiments in 
order to better visualize and count the effects of BrdU labelling in photographs taken 
with a digital camera. For determining cell proliferation, BrdU labelling reagent 
(RPN20 kit, GE Healthcare, Piscataway, NJ) was used as described above. 
Proliferation data are derived from between 450 to 600 cells measured in each group. 
 
Study 4. Levels of injury on glioma cell lines 
The two different cell lines (1321N1 and U87MG) were examined to determine the 
effect that T3 has on cell injury. When cells had reached confluence, approximately 
17000 cells /mm
2
 were placed in a 60 mm petri dish (n=8 for each dose) with T3 at 
doses of 0 nM, 1 nM and 500 nM for a period of 12, 24 and 48 hours.  
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Cellular injury was assessed by LDH enzyme release in the cultured medium. Culture 
medium (approximately 100 µl, n=8 for each dose) was collected at the end of the 
experiment for the measurement of lactate dehydrogenase (LDH) activity (IU/L) 
using an ELISA kit (Quantichrom LDH Kit, DLDH-100, BioAssay Systems, USA). 
Measurements were performed with Tecan Genios system. LDH release was 
expressed in each group as percentage of the non-treated group. 
 
Study 5. Levels of apoptosis in glioma cell lines 
The two different cell lines (1321N1 and U87MG) were examined to determine the 
effect that T3 has on cell apoptosis. When cells had reached the level of confluence, 
approximately 17000 cells /mm
2
 were placed in a 60 mm petri dish (n=8 for each 
dose) and treated with T3 at doses of 0 nM, 1 nM and 500 nM a period of 12, 24 and 
48 hours. After the treatment period apoptotic cell nuclei were assessed by the In Situ 
Cell Death Detection Kit, Fluorescein, according to the manufacturer’s instructions 
(ROCHE, Cat. No. 11 684 795 910).  Cell cultures were counterstained with Hoeschst 
33358 (5μg/ml) which stained the nuclei of all cells. 
 
Study 6. Molecular detection of kinase signalling in glioma cell lines 
The two different cell lines (1321N1 and U87MG) were examined to detect kinase 
signalling. When cells had reached confluence, 17000 cells /mm
2
 were placed in a 60 
mm petri dish (n=8 for each dose) treated with T3 at doses of 0 nM, 1 nM and 500 
nM for a period of 12, 24 and 48 hours. Cell lysis and isolation of proteins, 
determination of protein concentration and western blotting analysis for  
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phosphorylated and total Akt and ERK was performed as described above. Data were 
obtained from n=8 samples for each group. 
 
Study 7. Molecular detection of TRα1 receptors in glioma cell lines 
Two different cell lines (1321N1 and U87MG) were examined for the presence of 
thyroid receptor TRα1. Cell lysis and isolation of proteins, determination of protein 
concentration and western blotting analysis against TRα1 was performed as described 
above.  
 
2.5. Statistical analysis 
Values are presented as means +/- Standard Error of the Means (SEM). One-way 
analysis of variance (ANOVA) and Whitney- Mann tests were used for multiple 
comparisons between groups with the appropriate correction of Bonferroni or Dunnett 
T3. A two-tailed test with a p value less than 0.05 was considered significant.   
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Chapter Three 
 
 
Results 
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3.1. Studies in cardiac cell based models 
Study 1  
3.1.1. Cell geometry, shape and α-myosin in untreated neonatal cells 
Figure 3.1(A) shows the cell geometry in non-treated cells. The results show that 
staining of actin cytoskeleton with phalloidin showed that non-treated cardiomyocytes 
remained undifferentiated with an almost circular shape with poorly organized 
cytoskeleton. α-myosin  which characterizes the adult phenotype was not detected.  
 
3.1.2. Effect of TH on cell geometry, shape and growth in the absence (non-
treated) and presence (treated) of phenylephrine (PE)-treated cardiomyocytes 
Figure 3.1(B) shows the effect of PE treatment in cell geometry. The results show that 
PE treatment resulted in large cardiomyocytes with disoriented, dense myofibrils and 
cellular shape. PE increased cell growth as indicated by changes in total protein 
content and area. Total protein content (an index of hypertrophy) was increased 1.4 
fold in PE-treated as compared to non-treated cardiomyocytes, (P<0.05). Cell area 
was increased 1.3 (P<0.05) fold more in PE-treated as compared to non-treated 
cardiomyocytes, (P<0.05) (Figure 3.1). 
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Figure 3.1: Images of (A) non-treated and (B) PE-treated neonatal cardiomyocytes for 
5 days obtained by fluorescence microscopy after staining of actin cytoskeleton with 
phalloidin. Non-treated cardiomyocytes are of almost circular shape with poorly 
organized cytoskeleton, while PE treatment results in hypertrophied cardiomyocytes 
with disoriented, dense myofibrils and stellular shape. n=8, (20 x magnification). 
  
97 
 
3.1.3. Myosin heavy chain isoform expression in phenylephrine-treated neonatal 
cardiomyocytes 
 
PE-treated cardiomyocytes exhibited a 30% increase in β-MHC expression, p<0.05, as 
compared to non-treated cardiomyocytes.  α-MHC expression was not detected 
(Figure 3.2). 
 
 
Figure 3.2: (B) Densitometric assessment and representative images of  β-myosin 
heavy chain  isoform expression in non-treated neonatal cardiomyocytes and 
cardiomyocytes treated with phenylephrine (PE, 20 μM) for 5 days (A) Bar charts are 
means of optical ratios (arbitrary units), bar=SEM, n=8; * P<0.05 for PE-treated vs 
non-treated. 
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Figure 3.3: Images of (A) non-treated neonatal cardiomyocytes and (B) 
cardiomyocytes treated with phenylephrine (PE) for 5 days, obtained by fluorescence 
microscopy after staining for slow (β)-myosin with specific antibody. Immunostaining 
for β-myosin produced a stronger signal in PE-treated cardiomyocytes, as compared to 
non-treated; n=8, (20 x magnification). 
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3.1.4. Re-expression of TRα1 in phenylephrine-treated neonatal cardiomyocytes 
 
TRα1 protein expression was found to increase 4.5 fold in PE-treated neonatal 
cardiomyocytes as compared to non-treated cardiomyocytes, P<0.05 (Figure 3.4). 
 
 
 
 
 
Figure 3.4: (A) Densitometric assessment in arbitrary units and (B) representative 
western blots of thyroid hormone receptor α1 (TRα1) protein expression in non-
treated neonatal cardiomyocytes and cardiomyocytes treated with phenylephrine (PE, 
20 μM) for 5 days (Bar charts in (A) are means of optical ratios or arbitrary units, 
bar=SEM, n=8);  * P<0.05 for PE-treated vs non-treated. 
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Study 2 
 
3.1.5. Cell geometry and shape in T3-treated undifferentiated cardiomyocytes 
Administration of T3 induced a significant increase in the major / minor axis ratio 
(Figure 3.5). The major/minor axis ratio was found to be 2.2 ±0.14 in T3 treated cells 
as compared to 1.5 ±0.04 in non-treated cells, P<0.05 (Figure 3.6). This increase 
corresponded to a change in the cell shape from an almost circular to a more 
elongated form (Figure 3.5). 
 
 
 
 
Figure 3.5: Cell shape determined by the ratio of major to minor cell axis in non-
treated and T3-treated neonatal cardiomyocytes after 5 days*. P<0.05 for T3-treated 
vs non-treated; (n=8). 
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Figure 3.6: Images of (A) non-treated neonatal cardiomyocytes and (B) 
cardiomyocytes treated with T3 for 5 days, obtained by fluorescence microscopy after 
staining of actin cytoskeleton with phalloidin, n=8; (20 x magnification). 
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3.1.6. Cell area and protein synthesis in T3-treated undifferentiated 
cardiomyocytes 
 
The results presented in figure 3.7 show that the cell area was significantly increased 
(P<0.05) after 100 nM T3 treatment. In fact, cell area was 1.22 ±0.05 fold more in T3 
treated as compared to non-treated cells. 
Protein synthesis was also found to be significantly increased after T3 treatment. In 
fact, protein content was 1.3 ±0.06 fold more in T3 treated cells as compared to non-
treated cells, P<0.05 (Figure 3.8). 
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Figure 3.7-3.8: Cell area (A) and protein synthesis (B) in non-treated (open columns) 
and T3-treated (solid columns) neonatal cardiomyocytes after 5 days. Data are mean 
±SEM, * P<0.05 for T3-treated vs non-treated, n=8.  
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3.1.7. Myosin heavy chain isoform expression in T3-treated undifferentiated 
cardiomyocytes 
 
T3 treatment resulted in a switch of the isoform expression of myosin from the β-
isoform to the α-isoform. T3 cardiomyocytes expressed 100% α-MHC and no signal 
was detected by immunostaining for β-MHC as compared to untreated cardiomyocytes 
expressing 100% β- MHC (Figure 3.9).  
 
 
Figure 3.9: Image from electrophoresis showing myosin heavy chain isoform 
expression in non-treated neonatal cardiomyocytes and cardiomyocytes treated with 
T3 (T3) for 5 days. T3 treatment results in a switch of the isoform expression of 
myosin from the β-isoform to the α-isoform, typical of 8 such different experiments.  
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Figure 3.10: Images of (A) non-treated neonatal cardiomyocytes and (B) 
cardiomyocytes treated with T3 for 5 days, obtained by fluorescence microscopy after 
staining for slow (β)-myosin with specific antibody.  The signal of β-myosin was 
almost undetectable in T3 cardiomyocytes. n=8; (20 x magnification). 
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Study 3  
 
3.1.8. Cell geometry and shape in T3-treated dedifferentiated cardiomyocytes 
PE-treated cardiomyocytes were large with disoriented, dense myofibrils and almost 
stellular shape. Morphologically, PE+T3-treated cells exhibited an elongated shape, 
with a filamentous actin pattern organized into orderly arrays resembling that of T3-
treated cells (Figure 3.11). 
  
107 
 
 
 
 
Figure 3.11: Images of (A) cardiomyocytes treated with phenylephrine (PE) and (B) 
cardiomyocytes treated with phenylephrine and T3 (PE+T3) for 5 days, obtained by 
fluorescence microscopy after staining of actin cytoskeleton with phalloidin. n=8, (20 
x magnification). 
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3.1.9. Cell area and protein synthesis in T3 treated dedifferentiated 
cardiomyocytes 
 
T3 administration in PE-treated cardiomyocytes did not result in any change in cell 
area and protein synthesis. 
 
 
3.1.10. Myosin isoform expression in T3 treated dedifferentiated cardiomyocytes 
PE-treated cardiomyocytes expressed 100% β- MHC. In contrast, T3 administration in 
PE-treated cardiomyocytes resulted in significantly reduced (P<0.05) amount of β-
MHC (about 25% of the total myosin) and increased amount of α-MHC (about 75% of 
the total myosin) (Figure 3.12). 
The results presented in figure 3.12 also show that immunostaining for β-MHC 
resulted in a strong signal in PE-treated cardiomyocytes, while the signal was very 
weak in PE-T3 cardiomyocytes.  
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Figure 3.12: (A) Densitometric assessment in arbitrary units and (B) image of myosin 
heavy chain isoform expressions on cardiomyocytes treated with phenylephrine (PE) 
and  cardiomyocytes treated with phenylephrine and T3 (PE-T3) for 5 days (Columns 
are means of optical ratios, bar=sem n=8); **P<0.05 for PE+T3-treated vs PE.  
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Figure 3.13: Images of (A) cardiomyocytes treated with phenylephrine (PE) and (B) 
cardiomyocytes treated with phenylephrine and T3 (PE+T3) for 5 days obtained by 
fluorescence microscopy after staining for slow (β)-myosin with specific antibody. 
Immunostaining for β-myosin produced a strong signal in PE-treated cardiomyocytes, 
while the signal of β-myosin was almost undetectable in PE-T3 cardiomyocytes. n=8, 
(20 x magnification). 
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3.2. Studies in Glioma cell lines 
3.2.1. Growth curves of 1321N1 and U87MG cell lines 
Growth curves of the non-treated groups in both cell lines (1321N1 and U87MG) 
were constructed to show the cell state (still multiplying and not having reached a 
confluent level) at the selected time points. Cells were counted within a 4x4 grid and 
then further two grids were counted to gain an average. 
Figure 3.14 shows the growth curves of the two different cell lines between the non-
treated groups. According to these data, cells reached the peak of growth after the 
period of 98 hours, while at 144 hours cells reached a confluent level and their 
number started to decrease indicating that after this point there was no more space to 
grow. 
  
112 
 
 
 
 
Cell Number  
 
 
 
Figure 3.14: Time course growth curves showing the total number of 1321N1 and 
U87MG cells for the non-treated group over a period of 12, 24, 48, 96, and 144 hours. 
Data are mean of 8 experiments. 
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Generation of growth curves was necessary in evaluating the growth characteristics of 
each cell line under these conditions. From a growth curve, the population doubling 
time and saturation density can be determined. According to the data, cells reached 
the peak of growth after the period of 98 hours, while at 144 hours cells reached a 
confluent level and their number started to decrease indicating that after this point 
there was no more space to grow. Conclusions from these data were drawn indicating 
that the appropriate time-points to study the long-term effects of T3 were at 48 h and 
96 h. 
 
1321N1 Cell line 
3.2.2. Morphological characteristics of glioma cell lines 
3.2.2.1. Cell morphology-2 days 
Figures 3.16-3.18 show typical images of 1321N1 cells following incubation with 
either no T3 (untreated group, image 3.15), 1 nM T3 (figure 3.16), and 500 nM T3 
(figure 3.17). The results show that both 1 nM and 500 nM of T3 can induce the 
number of projections of the cells, but decreases the geometrical size of the cell 
compaired to untreated cells. These images were analysed and the data are presented 
in figure 3.18.  
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Figure 3.15: Image taken by phase-contrast optical microscopy. Characteristics such 
as cellular length, width, and number of projections in non-treated 1321N1 cell line 
after the period of 2 days are shown. This photograph is typical for n=8 such different 
experiments (20 x magnification). 
 
Figure 3.16: Image taken by phase-contrast optical microscopy. Characteristics such 
as cellular length, width, and number of projections in 1 nM T3-treated 1321N1 cells 
after the period of 2 days are shown. This photograph is typical for n=8 such different 
experiments (20 x magnification).  
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Figure 3.17: Image taken by phase-contrast optical microscopy. Characteristics such 
as cellular length, width, and number of projections in 500 nM T3-treated 1321N1 
cells after the period of 2 days are shown. This photograph is typical for n=8 such 
different experiments (20 x magnification). 
 
 
Figure 3.18 shows (A) the number of projections and (B) the shape of 1321N1 cells 
on 2 days following incubation with either 1 nM T3 or 500 nM T3 compared to the 
untreated group. The data show that treatment of 1321N1 glioma cells with 1 nM T3 
can result in a significant (p<0.05) increase in cell projections, but no change in the 
shape of the cells. The ratio of total number of projections to total number of cells was 
1.04 ±0.14 for non-treated vs 1.9 ±0.11 for 1 nM T3, p<0.05, and 2.0 ±0.14 for 500 
nM T3 treated cells, p<0.05 vs non-treated. 
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Figure 3.18: Bar charts showing changes in the number of projections (A) and ratio of 
cell length /width (B) of 1231N1 cell line after the period of 2 days. * p<0.05 for 
treated vs non-treated cells, n=8, Data are mean ±SEM.  
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3.2.2.2. Cell morphology-4 days 
Figures 3.19-3.21 show typical images of 1321N1 cells following 4 days of 
incubation with either no T3 (untreated group, image 3.19), 1 nM T3 (image 3.20), or 
500 nM T3 (image 3.21). Close observation of figures 3.20-3.22 shows the 
morphological difference of 1321N1 cell line over the period of 4 days between the 
non-treated group, and the groups treated with 1 nM and 500 nM T3 on the ratio of 
cell length /width and the number of projections. Cells were over confluent (over 
80%) after the period of 4 days and no quantitative data could be obtained regarding 
the measurement of number of projections and the ratio of cell length /width. 
 
Figure 3.19: Image taken by phase-contrast optical microscopy. In this and 
subsequent figures of images characteristics such as cellular length, width, and 
number of projections in non-treated 1321N1 cells after the period of 4 days are 
shown for comparison. This photograph is typical for n=8 such different experiments 
(20 x magnification). 
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Figure 3.20: Image taken by phase-contrast optical microscopy. Characteristics such 
as cellular length, width, and number of projections in 1 nM T3-treated 1321N1 cells 
after the period of 4 days are shown. This photograph is typical for n=8 such different 
experiments (20 x magnification). 
 
 
Figure 3.21: Image taken by phase-contrast optical microscopy. Characteristics such 
as cellular length, width, and number of projections in 500 nM T3-treated 1321N1 
cells after the period of 4 days are shown. This photograph is typical for n=8 such 
different experiments (20 x magnification).  
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3.2.3. Cell count of glioma cell lines 
3.2.3.1. Total cell number count 2 days 
Figure 3.22 shows the numbers of untreated and treated 1321N1 glioma cells 
following incubation with either 1 nM T3 or 500 nM T3 for 2 days. The results show 
that there was a significant increase (p<0.05) on the total number of the cells in both 
treatment groups (1 nM and 500 nM) in comparison with the non-treated group. Total 
number of cells were found to be 207183 ±2145 for non-treated vs 232366 ±2390 for 
1 nM T3, p<0.05, and 241283 ±2818 for 500 nM T3 treated cells, p<0.05 vs non-
treated.  
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Figure 3.22: Bar chart showing the total number of 1321N1 cells between the 
untreated and treated cells with either 1 nM or 500 nM T3 over a period of 2 days. 
Data are mean ±SEM, n=8; p<0.05 for treated cells compared to untreated cells. 
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3.2.3.2. Total cell count 4 days 
Figure 3.23 shows the numbers of untreated and treated 1321N1 glioma cells 
following incubation with either 1 nM T3 or 500 nM T3 for 4 days. The results show 
no significant differences (p>0.05) in the total number of the 1321N1 cells between 
the non-treated, 1 nM and 500 nM T3 treatment groups for the period of 4 days. 
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Figure 3.23: Bar chart showing the total number of 1321N1 cells between the 
untreated and treated cells with either 1 nM or 500 nM T3 over a period of 4 days. 
Data are mean ±SEM, n=8; Note that there was no significant differences between the 
data in either of the three groups. 
  
123 
 
3.2.4. Cell proliferation of glioma cell lines 
3.2.4.1. Cell proliferation-2 days 
Figures 3.24-3.26 show the nucleus of 1321N1 cells following incubation with either 
no T3 (untreated group, figure 3.24), 1 nM T3 (figure 3.25), and 500 nM T3 (figure 
3.26). The results show that either 1 nM or 500 nM of T3 can induce cell proliferation 
in comparison with the untreated group. 
 
 
Figure 3.24: A typical photograph showing the proliferation of the 1321N1 cells on 
the non-treated group. The nuclei that were stained black represent the cells that are 
replicating their DNA. This photograph is typical for n=8 such different experiments 
(20 x magnification). 
  
124 
 
 
Figure 3.25: A typical photograph showing the proliferation of the 1321N1 cells on 
the 1nM T3 treated group. The nuclei that were stained black represent the cells that 
are replicating their DNA. This photograph is typical for n=8 such different 
experiments (20 x magnification). 
 
Figure 3.26: A typical photograph showing the proliferation of the 1321N1 cells on 
the 500nM T3 treated group. The nuclei that were stained black represent the cells 
that are replicating their DNA. This photograph is typical for n=8 such different 
experiments (20 x magnification). 
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Figure 3.27 shows the proliferation percentage of 1321N1 glioma cells in untreated 
group and groups treated with either 1 nM or 500 nM T3 over a period of 2 days. The 
results have demonstrated a significant increase (p<0.05) in cell proliferation in both 
treatment groups (1 nM and 500 nM) in comparison with the non-treated group. The 
ratio was 23.6 ±3% in non-treated vs 30.5 ±3% in 1 nM T3, p<0.05, and 31.6 ±2% in 
500 nM T3 treated cells, p<0.05 vs non-treated. 
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Figure 3.27: Bar chart showing the percentages of cell proliferation of the 1321N1 
cell line for untreated group and groups treated with either 1 nM T3 or 500 nM T3 for 
2 days. Data are mean ± SEM, n=8; *p<0.05 for untreated cells compare to treated 
cells with 1 nM T3 or 500 nM T3. 
  
127 
 
3.2.4.2. Cell proliferation-4 days 
Figures 3.28-3.30 show the nucleus of 1321N1 cells following incubation with either 
no T3 (untreated group, figure 3.28), 1 nM T3 (figure 3.29), and 500 nM T3 (figure 
3.30). The results show no significant differences (p>0.05) between the groups after 
the period of 4 days. 
 
 
 
Figure 3.28: A typical photograph showing the proliferation of the 1321N1 cells on 
the non-treated group. The nuclei that were stained black represent the cells that are 
replicating their DNA. This photograph is typical for n=8 such different experiments 
(20 x magnification). 
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Figure 3.29: A typical photograph showing the proliferation of the 1321N1 cells on 
the 1 nM T3 treated group. The nuclei that were stained black represent the cells that 
are replicating their DNA. This photograph is typical for n=8 such different 
experiments (20 x magnification). 
 
Figure 3.30: A typical photograph showing the proliferation of the 1321N1 cells on 
the 500 nM T3 treated group. The nuclei that were stained black represent the cells 
that are replicating their DNA. This photograph is typical for n=8 such different 
experiments (20 x magnification).  
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Figure 3.31 shows the proliferation percentage of 1321N1 glioma cells in untreated 
group and groups treated with either 1 nM or 500 nM T3 over a period of 4 days. The 
results show no significant difference (p>0.05) between the non-treated and the T3 
treated groups on the 1321N1 cell line. The ratio was 45.2 ±5% in non-treated vs 40 
±6% in 1 nM T3, p>0.05, and 43.8 ±5% in 500 nM T3 treated cells, p>0.05 vs non 
treated. 
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Figure 3.31: Bar chart showing the percentage of cell proliferation of the 1321N1 cell 
line for untreated group and groups treated with either 1 nM T3 or 500 nM T3 for 4 
days. Data are mean ±SEM, n=8. Note that there was no significant difference in the 
percentage of cell proliferation between the groups.  
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3.2.5. Levels of injury on glioma cell lines 
3.2.5.1. Cell necrosis-2 days 
Figure 3.32 shows the percentage of LDH levels in the culture medium for untreated 
and treated 1321N1 cells incubated with either 1 nM or 500 nM for 2 days. The 
results show no significant difference (p>0.05) in the LDH levels between the three 
groups of the 1321N1 cell line for the 2 day treatment with T3. The ratio was 100 
±2.3% for non-treated vs 103.2 ±4.2% for 1 nM T3, p>0.05, and 100.2 ±4.1% for 500 
nM T3 treated cells, p>0.05 vs non-treated. These results indicated that no injury 
seems to take place in the cells following T3 treatment.  
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Figure 3.32: Bar charts showing the LDH release in culture medium in the three 
groups (non-treated, 1 nM, and 500 nM) of the 1321N1 cell line. The results are 
expressed as the percentage of the non-treated group, in comparison with the two 
treatment groups. Data are mean ±SEM, n=8; Note that there is no significant 
difference between the untreated and the 1 nM and 500 nM treatment groups. 
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3.2.5.2. Cell necrosis-4 days 
Figure 3.33 shows the percentage of LDH levels in the culture medium for untreated 
and treated 1321N1 cells incubated with either 1 nM or 500 nM for 4 days. The 
results show no significant difference (p>0.05) in the LDH levels between the three 
groups of the 1321N1 cell line for the 4 day treatment with T3. The ratio was 100 
±5.2 for non-treated vs 103.8 ±5.1% for 1 nM T3, p>0.05, and 108.2 ±4% for 500 nM 
T3 treated cells, p>0.05 vs non-treated. The results clearly show that T3 has no effect 
on 1321N1 cells even after 4 days of treatment.  
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Figure 3.33. Bar charts showing the LDH release in culture medium in the three 
groups (non-treated, 1 nM, and 500 nM) of the 1321N1 cell line. The results are 
expressed as the percentage of the non-treated group, in comparison with the two 
treatment groups. Data are mean ±SEM, n=8; Note that there is no significant 
difference between the untreated and the 1 nM and 500 nM treatment groups. 
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3.2.6. Levels of apoptosis on glioma cell lines 
3.2.6.1. Cell apoptosis-2 days 
The images in figures 3.34-3.35 show the nucleus of 1321N1 cells following 
treatment with 10 µl doxorubicin. Administration of doxorubicin is known to induce 
apoptosis and this drug was used as a positive control in order to certify the selected 
method. Apoptotic cell nuclei were assessed by TUNNEL staining using the In Situ 
Cell Death Detection Kit. 
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Figure 3.34: Image showing the apoptotic nuclei of the 1321N1 cells that were treated 
with doxorubicin. . The image was taken by fluorescence microscopy with a special 
filter for fluorescein detection. This photograph is typical for n=8 such different 
experiments (10 x magnification). 
 
Figure 3.35: Image showing all the nuclei of the 1321N1 cells that were treated with 
doxorubicin after counterstained with Hoeschst 33358. The image was taken by 
fluorescence microscopy with a special filter for Hoeschst 33358. This photograph is 
typical for n=8 such different experiments (10 x magnification). 
 
The images in figures 3.36-3.37 show the stained nucleus of 1321N1 cell line for the 
untreated cells over the period of 2 days. As shown on the images, there was no 
apoptotic cells on the untreated group of the 1321N1 cell line, in comparison with the  
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total number of cells stained on the figure 3.37. After the period of 2 days the cells 
were stained, and were viewed with a flurescence microscope.  
 
Figure 3.36: Image showing non-treated 1321N1 cells after staining for TUNNEL. No 
apoptotic cells were detected. This photograph is typical for n=8 such different 
experiments (10 x magnification). 
 
Figure 3.37: Image showing the total number of cells of the 1321N1 cell line on the 
non-treated group after staining with Hoeschst 33358. This photograph is typical for 
n=8 such different experiments (10 x magnification). 
The images in figures 3.38-3.39 show the stained nucleus of 1321N1 cell line for the 
1 nM T3 treated cells over the period of 2 days. As shown on the images, there was no 
apoptotic cells on 1 nM T3 group of the 1321N1 cell line, in comparison with the total   
138 
 
number of cells stained on the figure 3.39. After the period of 2 days the cells were 
stained, and were viewed with a fluorescence microscope.  
 
Figure 3.38: Image showing 1321N1 cells treated with 1 nM T3 after staining for 
TUNNEL. No apoptotic cells were detected. This photograph is typical for n=8 such 
different experiments (10 x magnification). 
 
Figure 3.39: Image showing the total number of 1321N1 cells treated with 1 nM T3 
after staining with Hoeschst 33358. This photograph is typical for n=8 such different 
experiments (10 x magnification). 
The images in figures 3.40-3.41 show the stained nucleus of 1321N1 cell line for the 
500 nM T3 treated cells over the period of 2 days. As shown on the images there was 
no apoptotic cells on 500 nM T3 group of the 1321N1 cell line, in comparison with   
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the total number of cells stained on the figure 3.41. After the period of 2 days the cells 
were stained, and were viewed with a fluorescence microscope. 
 
Figure 3.40: Image showing 1321N1 cells treated with 500 nM T3 after staining for 
TUNNEL. No apoptotic cells were detected. This photograph is typical for n=8 such 
different experiments (10 x magnification). 
 
Figure 3.41: Image showing the total number of 1321N1 cells treated with 500 nM T3 
after staining with Hoeschst 33358. This photograph is typical for n=8 such different 
experiments (10 x magnification). 
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3.2.6.2. Cell apoptosis 4 days 
The images in figures 3.42-3.43 show the nucleus of 1321N1 cells following 
treatment with 10 µl doxorubicin. Administration of doxorubicin is known to induce 
apoptosis and was used as a positive control in order to certify the selected method. 
Apoptotic cell nuclei were assessed by TUNNEL staining using the In Situ Cell Death 
Detection Kit. 
 
Figure 3.42: Image showing the apoptotic nuclei of the 1321N1 cells that were treated 
with doxorubicin. . The image was taken by fluorescence microscopy with a special 
filter for fluorescein detection. This photograph is typical for n=8 such different 
experiments (10 x magnification). 
 
Figure 3.43: Image showing all the nuclei of the 1321N1 cells that were treated with 
doxorubicin after counterstained with Hoeschst 33358. The image was taken by 
fluorescence microscopy with a special filter for Hoeschst 33358. This photograph is 
typical for n=8 such different experiments (10 x magnification).  
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The images in figures 3.44-3.45 show the stained nucleus of 1321N1 cell line for the 
untreated cells over the period of 4 days. As shown on the images, there was no 
apoptotic cells on the untreated group of the 1321N1 cell line, in comparison with the 
total number of cells stained on the figure 3.31. After the period of 4 days the cells 
were stained, and were viewed with a flurescence microscope.  
 
Figure 3.44: Image showing non-treated 1321N1 cells after staining for TUNNEL. No 
apoptotic cells were detected. This photograph is typical for n=8 such different 
experiments (10 x magnification). 
 
Figure 3.45: Image showing the total number of cells of the 1321N1 cell line on the 
non-treated group after staining with Hoeschst 33358. This photograph is typical for 
n=8 such different experiments (10 x magnification).  
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The images in figures 3.46-3.47 show the stained nucleus of 1321N1 cell line for the 
1 nM T3 treated cells over the period of 4 days. As shown on the images, there was no 
apoptotic cells on 1 nM T3 group of the 1321N1 cell line, in comparison with the total 
number of cells stained on the figure 3.47. After the period of 4 days the cells were 
stained, and were viewed with a fluorescence microscope.  
 
Figure 3.46: Image showing 1321N1 cells treated with 1 nM T3 after staining for 
TUNNEL. No apoptotic cells were detected. This photograph is typical for n=8 such 
different experiments (10 x magnification). 
 
Figure 3.47: Image showing the total number of 1321N1 cells treated with 1 nM T3 
after staining with Hoeschst 33358. This photograph is typical for n=8 such different 
experiments (10 x magnification).  
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The images in figures 3.48-3.49 show the stained nucleus of 1321N1 cell line for the 
500 nM T3 treated cells over the period of 4 days. As shown on the images, there was 
no apoptotic cells on 500 nM T3 group of the 1321N1 cell line, in comparison with 
the total number of cells stained on the figure 3.49. After the period of 4 days the cells 
were stained, and were viewed with a fluorescence microscope.  
 
Figure 3.48: Image showing 1321N1 cells treated with 500 nM T3 after staining for 
TUNNEL. No apoptotic cells were detected. This photograph is typical for n=8 such 
different experiments (10 x magnification). 
 
Figure 3.49: Image showing the total number of 1321N1 cells treated with 500 nM T3 
after staining with Hoeschst 33358. This photograph is typical for n=8 such different 
experiments (10 x magnification).  
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3.2.7. Molecular detection of kinase signalling in glioma cell lines 
3.2.7.1. Kinase signaling activation-2 days 
Figure 3.50 shows the analysis of the density of the Western blotting protein (B) and 
(A) the average of the optical density (arbitrary units) as obtained from the Western 
blotting experiment. The results show that after 2 days  the ratio of p44 and p42 
phospho-ERK to total ERK in 1321N1 cells was increased by 2.0 fold in the 1 nM 
T3-treated cultures (p>0.05) and by 2.6 fold in 500 nM T3-treated cells (p<0.05) as 
compared to non-treated cells. Although there was a dose dependent increase in p44 
and p42, the value was only significant on the 500 nM dose in comparison with the 
control group. 
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Figure 3.50: Bar charts in (A) show the ratio of phosphorylated to total p44 and p42 
ERKs in non-treated cells and after 1 nM and 500 nM treatment with T3 for 2 days. 
(The bars are the average of the optical density (arbitrary units), ±SEM) n=8. NT= 
non-treated, *p<0.05 vs non-treated. Figure (B) shows representative western blot of 
p44 and p42 phospho-ERK and total ERK.  
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Figure 3.51 shows the analysis of the density of the Western blotting protein (B) and 
(A) the average of the optical density as obtained from the Western blotting 
experiment. The results show that the ratio of phospho-Akt to total Akt was found to 
be 1.4 and 1.5 fold higher both in 1 nM and 500 nM T3 treated cells,  as compared to 
non-treated cells, p<0.05 after the 2 day treatment period. 
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Figure 3.51: Bar charts in (A) show the ratio of phosphorylated to total AKT in non-
treated cells and after 1nM and 500nM treatment with T3 for 2 days. (The bars are the 
average of the optical density (arbitrary units), ±SEM, n=8).NT=non-treated, * p<0.05 
vs non-treated. Figure (B) shows representatives of western blot of the AKT protein. 
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3.2.7.2. Kinase signaling activation-4 days 
Figure 3.52 shows the analysis of the density of the Western blotting protein (B) and 
(A) the average of the optical density as obtained from the Western blotting 
experiment. The results show that there were no differences in the ratio of p44 and 
p42 phospho-ERK to total ERK between the groups after the 4 day treatment period. 
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Figure 3.52: Bar charts in (A) show the ratio of phosphorylated to total p44 and p42 
ERKs in non-treated cells and after 1 nM and 500 nM treatment with T3 for 4 days. 
(The bars are the average of the optical density (arbitrary units), bar=SEM, n=8). 
NT=non-treated. Figure (B) shows representative western blot of p44 and p42 
phospho-ERK and total ERK. 
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Figure 3.53 shows the analysis of the density of the Western blotting protein (B) and 
(A) the average of the optical density as obtained from the Western blotting 
experiment. The results show that the ratio of phospho-Akt to total Akt was found to 
be 1.4 fold higher in 500 nM T3 treated cells as compared to non-treated and 1 nM T3 
treated cells (p<0.05) after the 4 day treatment period. 
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 Figure 3.53: Bar charts in (A) show the ratio of phosphorylated to total AKT in non-
treated cells and after 1 nM and 500 nM treatment with T3 for 4 days. (The bars are 
the average of the optical density (arbitrary units), bar=SEM, n=8). NT=non-treated. 
Figure (B) shows representatives of western blot of the AKT protein.  
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 U87MG Cell line 
3.3.1. Morphological characteristics of glioma cell lines 
3.3.1.1. Cell morphology 2 days 
Figures 3.54-3.56 show typical images of U87-MG cells following incubation with 
either no T3 (untreated group, image in fig 3.54), 1 nM T3 (image in figure 3.55), and 
500 nM T3 (image in figure 3.56). The results show that both 1 nM and 500 nM of T3 
can induce growth effects on the number of projections of the cells, but show no 
changes in the ratio of cell length /width compared to untreated cells. These images 
were analysed and the data are presented in figure 3.57.  
 
Figure 3.54: Image taken by phase-contrast optical microscopy. In this and 
subsequent image the data show characteristics such as cellular length, width, and 
number of projections in non-treated U87-MG cell line after the period of 2 days are 
shown for comparison. This photograph is typical for n=8 such different experiments 
(20 x magnification).  
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Figure 3.55: Image taken by phase-contrast optical microscopy. Characteristics such 
as cellular length, width, and number of projections in 1 nM T3-treated U87-MG cells 
after the period of 2 days are shown. This photograph is typical for n=8 such different 
experiments (20 x magnification). 
 
Figure 3.56: Image taken by phase-contrast optical microscopy. Characteristics such 
as cellular length, width, and number of projections in 500 nM T3-treated U87-MG 
cells after the period of 2 days are shown. This photograph is typical for n=8 such 
different experiments (20 x magnification).  
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Figure 3.57 shows (A) the number of projections and (B) the ratio of cell length 
/width of U87-MG cells on 2 days following incubation with either 1 nM T3 or 500 
nM T3 compared to untreated group. The results shown that treatment of U87-MG 
glioma cells with 1 nM T3 can result in a significant (p<0.05) increase in cell 
projections but no change in the geometry of the cells. The ratio of total number of 
projections to total number of cells was 1.16 ±0.14% for non treated vs 1.83 ±0.19% 
for 1 nM T3, p<0.05, and 2.0 ±0.19% for 500 nM, T3 treated cells, p<0.05 vs for non-
treated. 
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Figure 3.57: Bar charts showing changes on the number of projections (A) and the 
ratio of cell length /width (B) of the geometrical shape of U87-MG cell line after the 
period of 2 days. Data are mean±SEM * p<0.05 vs non-treated, n=8. 
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3.3.1.2. Cell morphology-4 days 
Figures 3.58-3.60 show typical images of U87-MG cells following 4 days of 
incubation with either no T3 (untreated group, image in figure 3.58), 1 nM T3 (image 
in figure 3.59), and 500 nM T3 (image in figure 3.60). Close observation of figures 
3.44-3.46 shows the morphological differences of U87-MG cell line over the period 
of 4 days between the non-treated group and the groups treated with 1 nM and 500 
nM T3 on both the ratio of length /width of the cell, and the number of projections. 
The cells were over confluent (over 80%) after the period of 4 days and no 
quantitative data could be obtained regarding the measurement of number of 
projections and the ratio of cell length /width. 
 
Figure 3.58: Image taken by phase-contrast optical microscopy. Characteristics such 
as cellular length, width, and number of projections in non-treated U87-MG cell line 
after the period of 2 days are shown. This photograph is typical for n=8 such different 
experiments (20 x magnification).  
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Figure 3.59: Image taken by phase-contrast optical microscopy. Characteristics such 
as cellular length, width, and number of projections in 1 nM T3-treated U87-MG cells 
after the period of 2 days are shown. This photograph is typical for n=8 such different 
experiments (20 x magnification). 
 
Figure 3.60: Image taken by phase-contrast optical microscopy. Characteristics such 
as cellular length, width, and number of projections in 500 nM T3-treated U87-MG 
cells after the period of 2 days are shown. This photograph is typical for n=8 such 
different experiments (20 x magnification).  
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3.3.2. Cell count of glioma cell lines 
3.3.2.1. Total cell number count 2 days 
Figure 3.61 shows the numbers of untreated and treated U87-MG glioma cells 
following incubation with either 1 nM T3 or 500 nM T3 for 2 days. The results show 
that there was a significant decrease (p<0.05) on the total number of the cells in both 
treatment groups (1 nM and 500 nM) in comparison with the non-treated group. The 
ratio of total number of cells was 211300 ±3000 for non-treated vs 186166 ±3122 for 
1 nM T3, p<0.05, and 18000 ±1833 for 500 nM T3 treated cells, p<0.05 vs non-
treated after a period of 2 days of treatment. 
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Figure 3.61: Bar charts showing the total number of U87-MG cells between the 
untreated and treated cells with either 1 nM or 500 nM T3 over a period of 2 days. 
Data are mean ±SEM, n=8; p<0.05 for treated cells compared to untreated cells. 
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3.3.2.2. Total cell count 4 days 
Figure 3.62 shows the numbers of untreated and treated U87-MG glioma cells 
following incubation with either 1 nM T3 or 500 nM T3 for 4 days. The results show 
there was a significant decrease (p<0.05) in the total number of the cells in both 
treatment groups (1 nM and 500 nM) in comparison with the non-treated group. The 
ratio of total number of cells was 396866 ±5791 for non-treated vs 331133 ±11652 for 
1 nM T3, p<0.05, and 310216 ±7090 for 500 nM T3 treated cells, p<0.05 vs non-
treated after the period of 4 day treatment. 
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Figure 3.62: Bar charts showing the total number of U87-MG cells between the 
untreated and treated cells with either 1 nM or 500 nM T3 over a period of 4 days. 
Data are mean ±SEM, n=8; *p<0.05 for treated cells compared to untreated cells. 
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3.3.3. Proliferation of glioma cell lines 
3.3.3.1. Cell proliferation 2 days 
Figures 3.63-3.65 show the nucleus of U87-MG cells following incubation with either 
no T3 (untreated group, figure 3.63), 1 nM T3 (image in figure 3.64), and 500 nM T3 
(image in figure 3.65). The results show that either 1 nM or 500 nM of T3 can 
significantly (p<0.05) decrease cell proliferation in comparison with the untreated 
group. 
 
 
Figure 3.63: A photograph showing the proliferation of the U87-MG cells on the non-
treated group. The nuclei that were stained black represent the cells that are 
replicating their DNA. This photograph is typical for n=8 such different experiments 
(20 x magnification). 
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Figure 3.64: A photograph showing the proliferation of the U87-MG cells on the 1 
nM T3 treated group. The nuclei that were stained black represent the cells that are 
replicating their DNA. This photograph is typical for n=8 such different experiments 
(20 x magnification). 
 
Figure 3.65: A photograph showing the proliferation of the U87-MG cells on the 500 
nM treated group. The nuclei that were stained black represent the cells that are 
replicating their DNA. This photograph is typical for n=8 such different experiments 
(20 x magnification).  
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Figure 3.66 shows the proliferation percentage of U87-MG glioma cells in untreated 
group and groups treated with either 1 nM or 500 nM T3 over a period of 2 days. The 
results show that there was a significant decrease (p<0.05) in cell proliferation in both 
the treatment groups in comparison with the non-treated group on the 2 day treatment. 
The ratio was 48 ±5% in non treated vs 23.6 ±4% in 1 nM T3, p<0.05, and 22 ±4% in 
500 nM T3 treated cells, p<0.05 vs non treated. 
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Figure 3.66: Bar charts showing the percentages of cell proliferation of the U87-MG 
cell line for untreated group and groups treated with either 1 nM T3 or 500 nM T3 for 
2 days. Data are mean ± SEM n=8;* p<0.05 for untreated cells compare to treated 
cells with 1 nM T3 or 500 nM T3.  
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3.3.3.2. Cell proliferation 4 days 
Figures 3.67-3.69 show the nucleus of U87-MG cells following incubation with either 
no T3 (untreated group, figure 3.67), 1 nM T3 (image in figure 3.68), and 500 nM T3 
(image in figure 3.69). The results show that 1 nM or 500 nM of T3 can decrease cell 
proliferation in comparison with the untreated group. 
 
 
Figure 3.67: A photograph showing the proliferation of the U87-MG cells on the non-
treated group. The nuclei that were stained black represent the cells that are 
replicating their DNA. This photograph is typical for n=8 such different experiments 
(20 x magnification). 
  
167 
 
 
Figure 3.68: A photograph showing the proliferation of the U87-MG cells on the 1 
nM T3 treated group. The nuclei that were stained black represent the cells that are 
replicating their DNA. This photograph is typical for n=8 such different experiments 
(20 x magnification). 
 
Figure 3.69: A photograph showing the proliferation of the U87-MG cells on the 500 
nM T3 treated group. The nuclei that were stained black represent the cells that are 
replicating their DNA. This photograph is typical for n=8 such different experiments 
(20 x magnification).  
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Figure 3.70 shows the proliferation percentage of U87-MG glioma cells in untreated 
group and groups treated with either 1 nM or 500 nM T3 over a period of 4 days. The 
results show that there was a significant decrease (p<0.05) in cell proliferation in both 
the treatment groups in comparison with the non-treated group on the 4 day treatment. 
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Figure 3.70: Bar charts showing the percentages of cell proliferation of the U87-MG 
cell line for untreated group and groups treated with either 1 nM T3 or 500 nM T3 for 
2 days. Data are mean ± SEM, n=8;* p<0.05 for untreated cells compare to treated 
cells with 1 nM T3 or 500 nM T3. 
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3.3.4. Levels of injury on glioma cell lines 
3.3.4.1. Cell necrosis 2 days 
Figure 3.71 shows the percentage of LDH levels in the culture medium for either 
untreated or treated U87-MG cells with either 1 nM or 500 nM incubated for 2 days. 
The results show that there was no significant difference (p>0.05) between the non-
treated group and the 1 nM T3 treated group for the period of 2 days, but the 500 nM 
T3 group showed a significant increase (p<0.05) of LDH levels in comparison to the 
non-treated and 1nM T3 groups. The ratio was 100 ±2% for non-treated vs 102.6 
±3.1% for 1 nM T3, p>0.05, and 120 ±7.2% for 500 nM T3 treated cells, p<0.05 vs 
non-treated and 1 nM. 
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Figure 3.71: Bar charts showing the LDH release in culture medium in the three 
groups (non-treated, 1 nM, and 500 nM) of the U87-MG cell line. The results are 
expressed as the percentage of the non-treated group, in comparison with the two 
treatment groups. Data are mean ±SEM, n=8; *p<0.05 for 500 nM T3 treated cells 
campaired with either non-treated or 1 nM T3 treated cells. Note that there is no 
significant difference between the untreated and the 1 nM treatment group. 
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3.3.4.2. Cell necrosis 4 days 
Figure 3.72 shows the percentage of LDH levels in the culture medium for untreated 
and treated U87-MG cells with either 1 nM or 500 nM incubated for 4 days. The 
results show that there was no significant difference (p>0.05) between the control 
group and the 1 nM T3 treated group for the period of 4 days, but the 500 nM T3 
group showed a significant increase (p<0.05) of LDH levels in comparison to the non-
treated and 1 nM T3 groups. The ratio was 100 ±3.2% for non-treated vs 104 ±3.1% 
for 1 nM T3, p>0.05, and 121 ±6.96% for 500 nM T3 treated cells, p<0.05 vs non-
treated and 1 nM. 
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Figure 3.72: Bar charts showing the LDH release in culture medium in the three 
groups (non-treated, 1 nM, and 500 nM) of the U87-MG cell line. The results are 
expressed as the percentage of the non-treated group, in comparison with the two 
treatment groups. Data are mean ±SEM, n=8; **p<0.05 for 500 nM treated cells 
compared to non-treated or 1 nM T3 treated cells. 
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3.3.5. Levels of apoptosis on glioma cell lines 
3.3.5.1. Cell apoptosis 2 days 
The images in figures 3.73-3.74 show the nuclei of U87-MG cells following treatment 
with 10 µl doxorubicin. Administration of doxorubicin is known to induce apoptosis 
and was used as a positive control in order to certify the selected method. Apoptotic 
cell nuclei were assessed by TUNNEL staining using the In Situ Cell Death Detection 
Kit. 
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Figure 3.73: Image showing the apoptotic nuclei of the U87-MG cells that were 
treated with doxorubicin. . Image was taken by phase-contrast fluorescence 
microscopy with a special filter for fluorescein detection. This photograph is typical 
for n=8 such different experiments (10 x magnification). 
 
Figure 3.74: Image showing all the nuclei of the U87-MG cells that were treated with 
doxorubicin after counterstained with Hoeschst 33358. Image was taken by phase-
contrast fluorescence microscopy with a special filter for Hoeschst 33358. This 
photograph is typical for n=8 such different experiments (10 x magnification). 
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The images in figures 3.75-3.76 show the stained nucleus of U87-MG cell line for the 
untreated cells over the period of 2 days. As shown on the images there was no 
apoptotic cells on the untreated group of the U87-MG cell line, in comparison with 
the total number of cells stained on the figure 3.76. After the period of 2 days the cells 
were stained, and subsequently viewed with a flurescence microscope. 
 
Figure 3.75: Image showing non-treated U87-MG cells after staining for TUNNEL. 
No apoptotic cells were detected. This photograph is typical for n=8 such different 
experiments (10 x magnification). 
 
Figure 3.76: Image showing the total number of cells of the U87-MG cell line on the 
non-treated group after staining with Hoeschst 33358. This photograph is typical for 
n=8 such different experiments (10 x magnification).  
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The images in figures 3.77-3.78 show the stained nucleus of U87-MG cell line for the 
1 nM T3 treated cells over the period of 2 days. As shown on the images there was no 
apoptotic cells on 1 nM T3 group of the U87-MG cell line, in comparison with the 
total number of cells stained on the figure 3.78. After the period of 2 days the cells 
were stained, and subsequently viewed with a flurescence microscope.  
 
Figure 3.77: Image showing U87-MG cells treated with 1nM T3 after staining for 
TUNNEL. No apoptotic cells were detected. This photograph is typical for n=8 such 
different experiments (10 x magnification). 
 
Figure 3.78: Image showing the total number of U87-MG cells treated with 1nM T3 
after staining with Hoeschst 33358. This photograph is typical for n=8 such different 
experiments (10 x magnification).  
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The images in figures 3.79-3.80 show the stained nucleus of U87-MG cell line for the 
500 nM T3 treated cells over the period of 2 days. As shown on the images there was 
no apoptotic cells on 500 nM T3 group of the U87-MG cell line, in comparison with 
the total number of cells stained on the figure 3.80. After the period of 2 days the cells 
were stained, and subsequently viewed with a flurescence microscope.  
 
Figure 3.79: Image showing U87-MG cells treated with 500 nM T3 after staining for 
TUNNEL. No apoptotic cells were detected. This photograph is typical for n=8 such 
different experiments (10 x magnification). 
 
Figure 3.80: Image showing the total number of U87-MG cells treated with 500 nM 
T3 after staining with Hoeschst 33358. This photograph is typical for n=8 such 
different experiments (10 x magnification).  
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3.3.5.2. Cell apoptosis 4 days 
The images in figures 3.81-3.82 show the nuclei of U87-MG cells following treatment 
with 10 µl doxorubicin. Administration of doxorubicin is known to induce apoptosis 
and was used as a positive control in order to certify the selected method. Apoptotic 
cell nuclei were assessed by TUNNEL staining using the In Situ Cell Death Detection 
Kit. 
 
Figure 3.81: Image showing the apoptotic nuclei of the U87-MG cells that were 
treated with doxorubicin. . Image was taken by phase-contrast fluorescence 
microscopy with a special filter for fluorescein detection. This photograph is typical 
for n=8 such different experiments (10 x magnification). 
 
Figure 3.82: Image showing all the nuclei of the U87-MG cells that were treated with 
doxorubicin after counterstained with Hoeschst 33358. Image was taken by phase-
contrast fluorescence microscopy with a special filter for Hoeschst 33358. This 
photograph is typical for n=8 such different experiments (10 x magnification).  
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The images in figures 3.83-3.84 show the stained nuclei of U87-MG cell line for the 
untreated cells over the period of 4 days. As shown on the images there was no 
apoptotic cells on the untreated group of the U87-MG cell line, in comparison with 
the total number of cells stained on the figure 3.84. After the period of 4 days the cells 
were stained, and subsequently viewed with a flurescence microscope.  
 
Figure 3.83: Image showing non-treated U87-MG cells after staining for TUNNEL. 
No apoptotic cells were detected. This photograph is typical for n=8 such different 
experiments (10 x magnification). 
 
Figure 3.84: Image showing the total number of cells of the U87-MG cell line on the 
non-treated group after staining with Hoeschst 33358. This photograph is typical for 
n=8 such different experiments (10 x magnification).  
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The images in figures 3.85-3.86 show the stained nuclei of U87-MG cell line for the 1 
nM T3 treated cells over the period of 4 days. As shown on the images there was no 
apoptotic cells on 1 nM T3 group of the U87-MG cell line, in comparison with the 
total number of cells stained on the figure 3.86. After the period of 4 days the cells 
were stained, and subsequently viewed with a flurescence microscope.  
 
Figure 3.85: Image showing U87-MG cells treated with 1 nM T3 after staining for 
TUNNEL. No apoptotic cells were detected. This photograph is typical for n=8 such 
different experiments (10 x magnification). 
 
Figure 3.86: Image showing the total number of U87-MG cells treated with 1 nM T3 
after staining with Hoeschst 33358. This photograph is typical for n=8 such different 
experiments (10 x magnification).  
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The images in figures 3.87-3.88 show the stained nuclei of U87-MG cell line for the 
500 nM T3 treated cells over the period of 4 days. As shown on the images there was 
no apoptotic cells on 500 nM T3 group of the U87-MG cell line, in comparison with 
the total number of cells stained on the figure 3.88. After the period of 4 days the cells 
were stained, and subsequently viewed with a flurescence microscope.  
 
Figure 3.87: Image showing U87-MG cells treated with 500 nM T3 after staining for 
TUNNEL. No apoptotic cells were detected. This photograph is typical for n=8 such 
different experiments (10 x magnification). 
Figure 3.88: Image showing the total number of U87-MG cells treated with 500 nM 
T3 after staining with Hoeschst 33358. This photograph is typical for n=8 such 
different experiments (10 x magnification).  
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3.3.6. Molecular detection of kinase signalling in glioma cell lines 
3.3.6.1. Kinase signalling activation 2 days 
Figure 3.89 shows the analysis of the density of the Western blotting protein (B) and 
(A) the average of the optical density (arbitrary units) as obtained from the Western 
blotting experiment for U87-MG cells. The results show no significant differences in 
the ratio of p44 and p42 phospho-ERK to total ERK after the 2 days of treatment.  
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Figure 3.89: (A) Bar charts showing the ratio of phosphorylated to total p44 and p42 
ERKs in non-treated cells and after 1 nM and 500 nM treatment with T3 for 2 days. 
(The bars are the average of the optical density (arbitrary units), ±SEM, n=8). NT= 
non-treated. (B) Representative samples of Western blot of phosphor and total ERK 
protein.  
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Figure 3.90 shows the analysis of the density of the Western blotting protein (B) and 
(A) the average of the optical density as obtained from the Western blotting 
experiment. The results show that the ratio of phospho-Akt to total Akt after 2 days in 
culture was found to be reduced in 1 nM and 500 nM T3 treated cells as compared to 
the non-treated group. However, this decrease was not statistically significant. 
  
186 
 
Figure 3.90: (A) Bar charts showing the ratio of phosphorylated to total AKT in non-
treated cells and after 1 nM and 500 nM treatment with T3 for 2 days. (The bars are 
the average of the optical density (arbitrary units), ±SEM, n=8). NT=non-treated. (B) 
Representative samples of Western blot of phospho and total AKT protein. 
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3.3.6.2. Kinase signalling activation 4 days 
Figure 3.91 shows the analysis of the density of the Western blotting protein (B) and 
(A) the average of the optical density as obtained from the Western blotting 
experiment in U87-MG cells. The results show no changes in the ratio of p44 and p42 
phospho-ERK to total ERK between the groups after the 4 day treatment period. 
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Figure 3.91: (A) Bar charts showing the ratio of phosphorylated to total p44 and p42 
ERKs in non-treated cells and after 1nM and 500nM treatment with T3 for 4 days. 
(The bars are the average of the optical density (arbitrary units), ±SEM, n=8). NT= 
non-treated. (B) Representative example of Western blot of phosphor and total ERK 
protein.   
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Figure 3.92 shows the analysis of the density of the Western blotting protein (B) and 
(A) the average of the optical density as obtained from the Western blotting 
experiment. The results show that the ratio of phospho-Akt to total Akt was decreased 
by 1.5 fold in 500 nM T3 treated cells as compared to non treated and 1 nM, T3 
treated cells, (p<0.05). 
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Figure 3.92: (A) Bar charts showing the ratio of phosphorylated to total AKT in non-
treated cells and after 1 nM and 500 nM treatment with T3 for 4 days. (The bars are 
the average of the optical density (arbitrary units), ±SEM, n=8; *p<0.05 for 500 nM 
T3 treated cells compared with either non-treated or 1 nM T3 treated cells). NT=non-
treated. (B) Representative example of Western blot of phosphor and total Akt 
protein. 
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3.3.7. Molecular detection of TRα1 receptors in glioma cell lines 
3.3.7.1. Thyroid hormone receptors expression 
Figure 3.93 shows (B) the protein expression of the TRα1 Thyroid hormone receptor 
between the cell lines 1321N1 and U87-MG after the treatment period of 4 days, and 
(A) the average of the optical density as obtained from the Western blotting 
experiment. As shown in the results, there was a 2.9 fold increase in the expression of 
TRα1 receptor for U87MG cells as compared to 1321N1, p<0.05. TRβ1 receptor was 
undetectable in both cell lines. 
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Figure 3.93: (A) Bar charts showing the TRα1and TRβ1 protein expressions between 
the two cell lines 1321N1 and U87 (the bars are average of the optical density 
(arbitrary units), ±SEM, n=8).* p<0.05 for U87-MG vs 1321N1. (B) Representative 
example of Western blot protein.  
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4.1. Discussion 
 
It is now well recognized that thyroid hormone (TH) may have a critical role in the 
pathogenesis and the progression of the diseases due to its regulatory action on cell 
differentiation, proliferation and cell survival (Mourouzis et al., 2011). TH has 
regenerative/reparative action under pathological conditions (Pantos et al., 2010; 
Pantos et al., 2011; Shulga et al., 2009). This unique effect could potentially be of 
therapeutic value in cancer therapy (Kress et al., 2009). 
Experimental and clinical studies provide a growing body of evidence that TH 
signalling may be altered in heart failure with important physiological and therapeutic 
consequences (Pantos et al., 2008). Similarly, alterations in TH signalling have been 
observed in malignancies (Aranda et al., 2009; Gonzalez-Sancho et al., 2003) and 
hypothyroidism is shown to enhance tumour invasiveness and metastasis development 
(Garcia-Silva et al., 2004; Martinez-Iglesias et al., 2009). Furthermore, in 1896, 
thyroxine (horse thyroid extract) was the first successful hormonal product to be used 
against a fulminating breast cancer (Beatson et al., 1896). Similar results were 
thereafter reported for a series of patients with breast cancer in 1954 (Loeser et al., 
1954). However, until now, the potential of TH as cancer therapy has not been 
adequately explored. 
This thesis first explored the potential effects of thyroid hormone to differentiate 
undifferentiated and/ or dedifferentiated cells due to growth stimuli in an established 
model of neonatal cardiomyocytes. 
These cells in a serum free environment remained undifferentiated. Then, the 
response of those cells to physiologic and pathologic growth stimuli was assessed. 
Cell size and shape, cytoskeleton organization and the pattern of myosin expression   
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were used as index of cell differentiation / dedifferentiation as previously described 
(Kinugawa et al., 2005). 
 
4.2. T3 has the ability to differentiate neonatal cardiomyocytes 
 
Non-treated cardiomyocytes remained undifferentiated with an almost circular shape 
with poorly organized cytoskeleton and did not express α-myosin which characterizes 
the adult phenotype. Addition of T3 promoted cell differentiation with cells to have an 
elongated shape, with a filamentous actin pattern organized into orderly arrays.  Those 
cells expressed 100% α-MHC and no signal was detected by immunostaining for β-
MHC as compared to untreated cardiomyocytes expressing 100% β- MHC.  These 
data clearly show that T3 is critical for the maturation of the myocytes during 
development and are in accordance with other studies.  
Thus, TH was shown to be critical in the maturation of embryonic heart-derived cells 
(H9c2), (van der Heide et al., 2007; van der Putten et al., 2002). In fact, intracellular 
T4 and T3 levels increase during the progression of cell differentiation with a 
concomitant increase in the expression of TRα1 and this response could be  prevented 
by pharmacological inhibition of thyroid hormone binding to TRα1 (Meischl et al., 
2008; Pantos et al., 2008c; van der Heide et al., 2007; van der Putten et al., 2002). 
Furthermore, TH was shown to stop proliferation and promote differentiation in fetal 
bovine cardiomyocytes.  Interestingly, this unique effect was shown to be achieved in 
nearly normal T3 concentrations and is mediated via T3 action on cyclin D1 and p21. 
(Chattergoon et al., 2011).  
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4.3. Phenylephrine (PE) induce dedifferentiation in neonatal cells 
In this model, PE, an alpha adrenergic receptor, agonist was shown to further 
dedifferentiate the neonatal cardiomyocytes. In fact, PE treatment resulted in large 
cardiomyocytes with disoriented, dense myofibrils and stellular shape. PE-treated 
cardiomyocytes exhibited a 30% fold increase in β-MHC expression, p<0.05, as 
compared to non-treated cardiomyocytes.  α-MHC expression was not detected.   
Interestingly, these cardiomyocytes were found to re-express TRα1 as this occurs 
during foetal life (White et al., 2001). Previous studies failed to show this effect since 
the authors measured only the total mRNA and not the expression of the protein in the 
nucleus (Kinugawa et al., 2005). 
 
4.4. T3 differentiates dedifferentiated cells 
Morphologically, PE-T3-treated cells exhibited an elongated shape, with a filamentous 
actin pattern organized into orderly arrays resembling that of T3-treated cells. T3 
administration in PE-treated cardiomyocytes resulted in significantly reduced amount 
of β-MHC (about 25% of the total myosin) and increased amount of α-MHC (about 
75% of the total myosin). These data reveal that T3 can reverse stress-induced 
dedifferentiation and this effect may be of physiological and therapeutic relevance. In 
fact, TH treatment early after coronary ligation in animals could favorably remodel the 
viable, non ischemic myocardium. TH accelerated the development of cardiac 
hypertrophy characterized by an adult pattern of MHC isoform expression. This 
response caused an early normalization of wall stress which is known to be a critical 
determinant of oxygen consumption and myocardial performance (Pantos et al., 2008). 
TH either early or late after myocardial infarction could reshape the heart from 
spherical to the elipsoid shape (Pantos et al., 2008; Pantos et al., 2009).   
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After showing that thyroid hormone has a unique ability to promote cell 
differentiation in heart cells, the present study further explored whether this can be of 
relevance in glioma tumour cells  
Gliomas represent the most common primary brain tumour and are among the most 
aggressive of cancers. Patients with glioma typically relapse within a year of initial 
diagnosis (Ohgaki et al., 2009). Although neurosurgical resection, radiation and 
chemotherapy provide clear benefit, prognosis remains disappointing. TH levels are 
shown to be low in patients with gliomas but the relevance of this response to the 
pathophysiology of the disease remains largely unknown (Nauman et al., 2004). 
 
4.5. Glioma cell line models  
Cell models of glioma tumours are available for decades but the extent to which these 
models recapitulate the human disease remains debatable (Jacobs et al., 2011).  Two 
different glioma cell lines, the 1321N1, an astrocytoma grade II, and U87MG, a 
glioblastoma grade IV cell line were used in this study. Both cell lines are shown to 
express Akt (Koul et al., 2006; Toll et al., 2011) which is a frequent finding in 
gliomas (Pollack et al., 2010). 
U87 MG is the most commonly studied brain cancer cell line and is highly 
cytogenetically aberrant as genomic decoding has recently revealed (Clark et al., 
2010). This cell line is PTEN deficient and resistant to conventional therapy 
(Premkumar et al., 2012) PTEN is a well studied tumour suppressor gene that is 
mutated or deleted in various cancers including glioma (Parson et al., 2008) and the 
lack of it is implicated in  resistance  to chemotherapy and radiation (Hanahan et al.,   
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2011). Here, it should be noted that the longest survival of patient with glioma was 
shown to be associated with a molecular profile including PTEN tumour suppressor 
gene positive and Akt negative (Sperduto and Chakravarti, 2009) 
 
4.6. Thyroid hormone (TH) and brain tumours  
Thyroid hormone is essential for the proper development of numerous tissues, notably 
the brain. The entry of T4 and T3 via the blood-brain barrier appears to be the 
preferred route for the distribution of thyroid hormone in the brain, whereas the 
uptake via choroid plexus–CSF barrier is thought to be necessary to provide 
circumventricular areas with sufficient amounts of thyroid hormone (Dratman, et al., 
1991). After passing these barriers, T4 has to be taken up by astrocytes for further 
activation and finally T3 has to enter neuronal cells, which not only express TRs but 
also participate in the inactivation of T4 and T3 by expressing D3 (Heuer, 2003). 
The action of T3 in relation to brain tumours has not been adequately explored. 
Preliminary experimental studies provide evidence showing that acute, short-term TH 
treatment may increase cell proliferation and survival via its non genomic action 
(Davis et al., 2006; Lin et al., 2009; Lin et al., 2008). However, this effect may not be 
sustained and long-term TH treatment appears to suppress cell proliferation in 
neuroblastoma cells (Garcia-Silva et al., 2004). Most of those studies have looked at 
the effect of thyroid hormone on cell proliferation and not on cell differentiation and 
induction of cell necrosis. Furthermore, there are no data regarding potential changes 
in thyroid hormone receptors in experimental glioma cell lines. 
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T3 was used as chronic treatment since T4 acts on the cell membrane and has no 
genomic long acting effects. Cells deprived of T3 in medium were used as controls (0 
nM, untreated). Two doses of T3 were used based on previous data (Lebel et al., 
1994; Aranda et al., 2004). Thus, cells were treated with 1 nM which is a near 
physiologic dose and clinically relevant. A second dose of 500 nM was used as 
supraphysiological dose. The effects of T3 were assessed in two time points; 48 h and 
96h. This was based on the data obtained from the construction of growth curves and 
from previous studies showing that the effect of T3 on cell differentiation was peaked 
at 48h (Lebel et al., 1994). The effect of T3 on cell proliferation was assessed by 
BrdU labeling (Garcia –Silva et al., 2004). Cell differentiation was assessed by 
morphology studies (Lebel et al., 2004). Apoptosis was assessed by TUNNEL 
staining and cellular necrosis was measured by LDH release (Tamura et al., 2000).  
 
4.7. T3 effect on glioma cell differentiation  
 
T3 at concentration of 1 nM and 500 nM resulted in cell re-differentiation in both cell 
lines studied as indicated by the morphological changes and the marked increase in 
the number of perisomatal filopodia like neurites. This finding is in accordance with 
previous reports showing a transforming effect of T3 in neuroblastoma cells (Garcia-
Silva et al., 2004). A series of genes related to neuroblastoma cell differentiation are 
shown to be responsive to TH (Bebo et al., 2011). It is of note that this unique effect 
of TH has also been shown in other cancer cells and may be of physiological and 
therapeutic relevance (Perra et al., 2009). 
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4.8. T3 effect on cell growth and survival  
 
T3 at concentration of 1 nM had a differential effect on cell growth between the two 
cell lines as indicated by the total cell number count. Thus, in 1321N1, T3 treatment 
significantly increased total cell number at 2 days which declined thereafter. On the 
contrary, in the U87MG cell line, total cell number was markedly decreased both at 2 
and 4 days with T3 incubation. Changes in cell numbers may reflect alterations in cell 
proliferation and /or cell injury (cell necrosis and / or apoptosis). In order to address 
this issue we measured cell proliferation using BrdU labelling reagent added to the 
medium and LDH release in medium  for cell  necrosis and TUNNEL staining using 
the In Situ Cell Death Detection Kit for cell apoptosis. The results showed that T3 had 
no effect cell injury but had a differential effect on cell proliferation. In fact, in 
1321N1, T3 treatment resulted in increased cell proliferation at two days which 
declined thereafter and in the U87MG cell line, T3 markedly suppressed cell 
proliferation which was evident both at two and four days. Taken together, these data 
clearly show that near physiological T3 concentrations can reduce glioma growth in 
the more aggressive type via its effect on cell proliferation (Pantos et al., 2012).  
T3 at the higher concentration had also a differential effect on cell growth between the 
two cell lines as indicated by the total cell number count. Thus, in 1321N1, T3 
treatment significantly increased total cell number at 2 days which declined thereafter. 
This was due to T3 effect on cell proliferation: T3 treatment resulted in increased cell 
proliferation at two days which declined thereafter. In U87MG cell line, total cell 
number was markedly decreased both at 2 and 4 days with T3 incubation. This was 
found to be due to the effect of T3 both on cell proliferation and cell survival. In fact, 
T3 at high concentration not only inhibited cell proliferation but also caused a marked   
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increase in cell injury in the form of cell necrosis as indicated by the LDH release. 
Similar result has not been previously reported since there is no study which has 
investigated potential effect of T3 on glioma cell survival. 
 
4.9. Molecular aspects of T3 action on glioma tumours  
 
4.9.1. The potential role of TR receptors  
 
The potential underlying mechanisms of TH on glioma cell growth are not fully 
understood. Long-term TH effects are mediated via thyroid hormone receptors (TRs). 
TRs are transcription factors which regulate important genes related to cell 
differentiation, proliferation and survival (Kress et al., 2009). It is now recognized 
that TRs are altered in pathological conditions with important physiological 
consequences. Thus, it has previously been shown that TRs can change under 
pathological conditions such as myocardial ischaemia or in cardiac cells exposed to 
growth stimuli (Pantos et al., 2011; Pantos et al., 2008). Similarly, there is increasing 
evidence that alterations in TRs are common events in cancer (Pantos et al., 2010). 
The evidence demonstrating that the mutated TR could be involved in carcinogenesis 
came from the discovery that TRα1 is the cellular counterpart of the retroviral v-erbA 
that is involved in the neoplastic transformation leading to acute erythroleukemia and 
sarcomas (Sap, et al., 1986; Thormeyer and Baniahmad, 1999). It was shown that V-
erbA itself has a weak oncogenic activity but it augments the transformation activity 
of other oncoproteins (Cheng, 2003).V-erbA competes with TR for binding to TREs 
and interferes with the normal transcriptional activity of liganded-TR on several 
promoters (Yen et al., 1994; Chen and Privalsky, 1993). V-erbA oncoprotein is   
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thought to repress constitutively, through its dominant negative activity, a certain set 
of genes that prevent cellular transformation (Cheng, 2003). 
Further evidence, which involves the mutated TRs in carcinogenesis, comes from 
from the identification that cyclin D1, a known oncogene product, and p53, a known 
suppressor can physically interact with TRβ1 (Cheng, 2003). It was found that p53 
interacts with TRβ1 in vitro and in cultured cells an interaction that results in 
repression of the transcriptional activity of TRβ1 (Bhat, et al., 1997). Cyclin D1 
associates with C-terminal region of the ligand-binding domain of TRβ1 in vitro and 
in vivo and acts to repress the transcriptional activity of TRβ1, α1 and β2 (Lin et al., 
2002). 
TR receptors are shown to have a tumour suppressor effect. Thus, mice expressing a 
dominant negative TRβ mutant present in some patients with thyroid hormone 
resistance syndrome spontaneously develop metastatic carcinoma (Suzuki et al., 
2002). Expression of TRβ1 was shown to abolish totally tumour formation by ras –
transformed cells in nude mice, even under hypothyroid conditions and block to a 
significant extent fibroblast transformation by ras in the absence of exogenously 
added ligand. On the other hand, tumour formation is reduced in euthyroid mice 
inoculated with cells expressing ras oncogene and TRα1, but all hypothyroid animals 
develop tumours. Thus, TRα1 has a ligand –dependent antitransforming activity 
(Garcia-Silva et al., 2004). 
On the basis of this evidence, the present study explored whether altered TR 
expression in these two cell lines could possibly underlie the differential T3 effect on 
cell proliferation. Interestingly, TRα1 was found to be over expressed in U87MG cell 
line compared to 1321N1, while TRβ1 receptor was undetectable in both cell lines. 
This finding may indicate a potential implication of TRα1 receptor in T3 action on   
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glioma cell tumours. In fact, T3 was shown to have   no effect on neuro-2a cells in 
which TRα2 receptor expression was dominant and inhibited TRα1 which was hardly 
expressed (Lebel et al., 1994). 
TRα1 receptor has a unique dual mode of function depending on thyroid hormone 
availability. Thus, TRα1 in its un-liganded state (aporeceptor) instead of being 
inactive exerts repressive or inducible effect on the transcription of T3 inducible or 
repressive genes by recruiting co–repressor complexes with histone deacetylase 
(Zhangand et al., 2000). This is of important physiological relevance during 
development with TRα1 to be over-expressed at early embryonic stages when TH is 
low, resulting in cell proliferation and declines thereafter with the rise of TH resulting 
in cell differentiation (Mourouzis et al., 2011). This foetal pattern of TRα1 expression 
re-emerges under pathological conditions and may lead to pathological hypertrophy 
(Pantos et al., 2011; Pantos et al., 2008) or promote cell cancer proliferation (Garcia-
Silva et al., 2004). The addition of TH prevents pathological growth and stops cancer 
cell proliferation by converting the un-liganded TRα1 to liganded receptor (Pantos et 
al., 2011, Pantos et al., 2008; Garcia-Silva et al., 2004) (Figure 4.1). This ligand 
dependent antitransforming activity of thyroid hormone receptor is unique for the 
TRα1. In fact, over-expression of TR β1 was shown to abolish tumour formation by 
ras –transformed cells in nude mice, even under hypothyroid condition (Garcia-Silva 
et al., 2004). 
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Figure 4.1. A schematic diagram showing the role of TRα1 in the response of the cell 
to growth stimuli. The present study and previous reports provide evidence that T3 
can convert pathological growth to physiologic growth and re-differentiate 
cardiomyocytes or cancer cells (Taken from a Power point presentation).  
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4.9.2. TRα1: a common player in pathological cardiac growth and cancer 
An interesting finding of this study was that TRα1 receptor was found to be re-
expressed both in pathologic growth induced by (PE) and glioma tumour cells. This 
probably indicates that a common mechanism which returns the cells to fetal 
phenotype in response to stress may exist (Pantos et al., 2011). More importantly, the 
fact that the addition of thyroid hormone could reverse this response probably 
indicates that TRα1 is a critical molecular switch that regulates the process of cell 
differentiation /dedifferentiation in response to stress. TRα1 may be pharmacologicaly 
targeted and novel treatments for cancer and heart failure may emerge (Pantos et al., 
2011). However, this issue merits further investigation in future studies. 
 
4.9.3. The potential role of growth signalling 
Complex signaling pathways are implicated in cell growth and survival. Interestingly, 
growth and cell response to injury share common pathways. Akt and ERK are the 
most studied kinase signalling in cell growth and survival (Chappell et al., 2011; Hers 
et al., 2011; Lo et al., 2011). 
Akt deliver antiapoptotic signals via different proteins directly modulated by Akt 
phosphorylation. Bad is one of the first discovered targets of Akt phosphorylation.Bad 
is a proapoptotic member of the Bcl-2 family of proteins, able to bind Bcl-2 or Bcl- 
XL, blocking their antiapoptotic activities. Phosphorylation of Bad on S136 by Akt 
disrupts its interaction with Bcl- 2/Bcl-XL, localized on the outer mitochondrial 
membrane, sequestering Bad in the cytosol through the interaction with 14-3-3 
protein. In an analogous way, phosphorylation of proapoptotic Bax protein by Akt on 
S184 suppresses its translocation to mitochondria, preventing Bax conformational 
change, a typical event that occurs after apoptotic induction. In addition, the caspase   
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cascade is further inhibited by Akt phosphorylation of pro-caspase 9, inactivated 
through phosphorylation in S196, a residue that, however, is not conserved in other 
mammalian species.  
One of the best-conserved functions of Akt is its role in promoting cell growth. The 
predominant mechanism appears to be through activation of the mammalian target of 
rapamycin complex 1 (mTORC1), which is regulated by both nutrients and growth 
factor signalling.  Akt-mediated cell proliferation and oncogenic transformation has 
been shown to be dependent on mTORC1 activation (reviewed by Bononi et al.,  
2011). 
The ERK signalling pathway plays a role in several steps of tumour development. The 
phosphorylation by ERK of proteins such as myosin light chain kinase, calpain, focal 
adhesion kinase, and paxillin promotes cancer cell migration. The ERK pathway also 
induces the expression of matrix metalloproteinases and thereby promotes the 
degradation of extracellular matrix proteins and consequent tumour invasion 
Furthermore, ERK1/2 signaling regulates the activities and levels of Bcl-2 family 
proteins such as the pro-apoptotic protein BIM and the anti-apoptotic protein MCL-1, 
thereby promoting the survival of cancer cells. The ERK signalling pathway is 
therefore considered a prominent therapeutic target for the development of 
chemotherapeutic drugs, with sorafenib, a Raf inhibitor, being one of the most 
efficient drugs available (Tanimura et al., 2002; Welch et al., 2000). 
Akt and ERK have been associated with glioma tumour aggressiveness (Pollack et al., 
2010; Fanand et al., 2011; Robinson et al., 2011).  The present study showed that T3 
treatment in glioma cell lines could induce distinct changes in Akt and ERK 
activation (assessed by measuring the phosphorylated levels of these kinases). Thus, 
T3, at 1 nM, significantly increased p-Akt levels in 1321N1 and not in U87MG cell   
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line while had no effect on ERK activation in either cell line. With the higher 
concentration, T3 increased both Akt and ERK activation in 1321N1 without any 
effect on ERK activation in U87MG. However, T3 at this dose resulted in marked 
decrease of Akt activation and this finding may offer an explanation of the observed 
increased cell injury with the use of this dose. Interestingly, progesterone, at high 
dose, was also shown to induce cell injury in neuroblastoma by suppressing Akt 
activation (Atif et al., 2011). Similarly, tamoxifen induced apoptosis of rat C6 glioma 
by suppressing Akt phosphorylation in a time dependent manner (Feng and Huang 
2010). Taken together, it appears that hormones may induce cell injury in gliomas by 
targeting the Akt pathway. Akt remains an important target to induce apoptosis in 
glioma cells. In fact, although therapies targeting pro-apoptotic pathways can also 
increase cell injury, cells that lack PTEN and overexpress Akt such as U87 remain 
resistant to those treatments (Premkumar et al., 2012). 
Tables 4.1 and 4.2 summarize the major findings of this study employing 1321N1 and 
U87-MG glioma cell lines for the period of 2 and 4 days of treatment with T3. The 
results show that following 2 days of treatment, T3 can affect cell differentiation in 
both the cell lines as well as the cell number of the cells showing an increase on both 
doses on the 1321N1 cells in comparison with the reduction of cell number on the 
U87-MG cells. The changes on the cell number come as a result of cell proliferation 
which is increased in both doses on the 1321N1 cells, and decreased in both doses on 
the U87-MG cells. The Akt pathway plays an important role for the changes happen 
to both cell lines after the 2 days treatment period. 
The results following the 4 days treatment period show that T3 can affect cell 
differentiation in both the cell lines but show a reduction on the cell number and cell 
proliferation in both doses only in the U87-MG cells. Cell necrosis is increased only   
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on the 500 nM dose in the U87-MG cells. The ERK pathway plays an important role 
for the changes happen to the U87-MG cells. 
The results for the effect of TH treatment on cardiomyocytes are summarized in Table 
4.3. The data show that both PE and TH treatments can result in significant increase 
in cell geometry, cell growth, cell protein synthesis and the expression of TRα1 
receptor in comparison with the non-treated cells. 
 
 
Table. 4.1. Summary of main results after 2 days T3 treatment 
 1321N1 Cell line U87 Cell line 
 1nM T3 500nM T3 1nM T3 500nM T3 
Cell differentiation + + + + 
Cell number Increased    Increased Reduced Reduced 
Cell proliferation + + - - 
Apoptosis ND ND ND ND 
Necrosis No change No change No change + 
Phospho-Akt  
levels 
Increased Increased No change No change 
Phospho-ERK 
levels 
No change Increased No change No change 
 
“+” represents induction, “-” represents inhibition, ND represents not detected 
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Table.4.2. Summary of main results after 4 days T3 treatment 
 1321N1 Cell line U87 Cell line 
 1nM T3 500nM T3 1nM T3 500nM T3 
Cell differentiation + + + + 
Cell number No change No change Reduced Reduced 
Cell proliferation No change No change - - 
Apoptosis ND ND ND ND 
Necrosis No change No change No change + 
Phospho-Akt 
 levels 
No change No change No change No change 
Phospho-ERK 
levels 
No change No change No change Decreased 
 
“+” represents induction, “-” represents inhibition, ND represents not detected 
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Table 4.3. Summary of main results on cardiomyocyte cells after PE and T3 
treatment 
 Non-treated PE T3 
Cell growth ND Increased Increased 
Cell area ND Increased Increased 
Protein 
synthesis 
Reduced ND Increased 
α-MHC ND ND Increased 
β-MHC Increased Increased ND 
TRα1 Reduced Increased Increased 
 
ND represents not detected 
  
211 
 
4.10. Conclusion 
Tables 4.1, 4.2 and 4.3 summarize the major findings of this study. The results show 
that T3 may reverse pathological growth in cardiac cells and re-differentiate glioma 
tumour cells due to its unique regulatory action on cell differentiation. In 
cardiomyocytes T3 has the ability to differentiate neonatal cells and PE induces 
dedifferentiation on those cells. In gliomas, T3 effect on cell proliferation appears to 
be dependent on the type of tumour cell line with aggressive tumours to be more 
sensitive to thyroid hormone treatment. TRα1 receptor may, at least in part, be 
implicated in this response. 
 
4.11. Clinical and therapeutic relevance –future directions  
These preliminary results may be the basis of further investigation to better clarify the 
effects of T3 on glioma treatment. It appears that physiological doses may be 
sufficient to control growth in glioma tumours. In fact, it has been shown that T3 
levels are low in patients with glioma (Nauman et al., 2004) and thus, T3 replacement 
therapy may be of value. This has to be tested in small clinical trials. A beneficial 
effect of the combination treatment with radiotherapy and thyroid hormone has been 
previously reported (Morales et al., 1988).  
212 
 
4.12. Scope for future studies 
1. Investigating the cellular mechanisms of contraction of the cardiomyocytes by 
measuring intracellular free Ca
2+
 concentrations, L-type Ca
2+ 
channel activities and 
contraction using established physiological methods as fluorometry, patch clam and 
video edge techniques. These experiments can be done in the absence and presence of 
TH and the cardiomyocytes will be stimulated electrically. 
2. Investigating the possible effects of T3 on other glioma cell lines with different 
grades and different levels of agressivness. The experiments will involve measuring 
cell growth, cell geometry, cell proliferation, cell injury, and the expressions of TRα1 
and other kinases. 
3. Investigating the effects of different growth factors on differentiated and 
dedifferentiated glioma cell lines, measuring the same parameters as described in this 
thesis. 
4. Investigating the effects of T3 on a clinical level on patients with glioma and to see 
the effects in comparison with radiotherapy. 
5. Investigating if patients with glioma tumours express TRα1 receptor. 
6. Investigating the effect of T3 and T4 treatments on primary glioma taken from 
patients. These experiments will involve tissue culture, cell geometry and expression 
of TH receptors and a number of kinases similar to these shown in this thesis.      
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Abstract 
Purpose. The present study investigated the potential effects of long-term T3 
treatment on glioma tumor cell lines. Thyroid hormone action on cell growth, 
differentiation and survival during development may be of therapeutic relevance 
Methods and Results 1321N1 cell line, an astrocytoma grade II, and U87MG, a 
glioblastoma grade IV, were exposed for 2 and 4 days in medium deprived of T3 and 
in medium containing 1 nM T3. T3 promoted re-differentiation in both cell lines. 
However, T3 increased cell proliferation in 1321N1 (2 days) which declined thereafter 
(4 days) while in U87MG resulted in suppression of cell proliferation. At the 
molecular level, a 2.9 fold increase in the expression of TRα1 receptor was observed 
in U87MG versus 1321N1, P < 0.05. TRβ1 receptor was undetectable. These changes 
corresponded to a distinct pattern of T3-induced kinase signaling activation; T3 had 
no effect on ERK activation in both cell lines but significantly increased phospho-Akt 
levels in 1321N1. Conclusion. In conclusion, T3 can re-differentiate glioma tumor 
cells, whereas its effect on cell proliferation appears to be dependent on the type of 
tumor cell line with aggressive tumors being more sensitive to T3. TRα1 receptor 
may, at least in part, be implicated in this response.  
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